PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"31748482","[Retrospective Examination of Usefulness and Adverse Effects of Tapentadol in Patients with Cancer Pain during Anticancer Treatment]","Shikada Y, Emi Y, Kometani T, Ochiai T, Fujii M, Noda Y, Kajiwara M, Miyazaki S, Asonuma S, Mori M.","Gan To Kagaku Ryoho. 2019 Nov;46(11):1727-1731.","Shikada Y","Gan To Kagaku Ryoho","2019","2019/11/22","","",""
"31682335","Tapentadol Dependence: A Case Series","Kathiresan P, Pakhre A, Kattula D, Sarkar S.","Prim Care Companion CNS Disord. 2019 Oct 31;21(5):19l02444. doi: 10.4088/PCC.19l02444.","Kathiresan P","Prim Care Companion CNS Disord","2019","2019/11/05","","","10.4088/PCC.19l02444"
"31471393","Shining a Light on the Effects of the Combination of (-)-Epigallocatechin-3-gallate and Tapentadol on the Growth of Human Triple-negative Breast Cancer Cells","Bimonte S, Cascella M, Barbieri A, Arra C, Cuomo A.","In Vivo. 2019 Sep-Oct;33(5):1463-1468. doi: 10.21873/invivo.11625.","Bimonte S","In Vivo","2019","2019/09/01","PMC6754998","","10.21873/invivo.11625"
"31166900","[Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review]","Vieira C, Brás M, Fragoso M.","Acta Med Port. 2019 May 31;32(5):388-399. doi: 10.20344/amp.10500. Epub 2019 May 31.","Vieira C","Acta Med Port","2019","2019/06/06","","","10.20344/amp.10500"
"31140915","Recurrence of complex regional pain syndrome after administration of adenosine","Roldan CJ, Lo TC, Huh B.","Pain Manag. 2019 May;9(3):233-237. doi: 10.2217/pmt-2018-0059. Epub 2019 May 29.","Roldan CJ","Pain Manag","2019","2019/05/30","","","10.2217/pmt-2018-0059"
"31061323","Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database","Suga Y, Uchida M, Suzuki S, Sugawara H, Torigoe K, Futamura A, Uesawa Y, Nakagawa T, Takase H.","Biol Pharm Bull. 2019;42(5):801-806. doi: 10.1248/bpb.b18-00997.","Suga Y","Biol Pharm Bull","2019","2019/05/08","","","10.1248/bpb.b18-00997"
"30929296","Combination pharmacotherapy for tackling descending controls and central sensitization","Treede RD, Schuh-Hofer S, Magerl W, La Porta C, Tappe-Theodor A.","Eur J Pain. 2019 Jul;23(6):1049-1050. doi: 10.1002/ejp.1396. Epub 2019 Apr 30.","Treede RD","Eur J Pain","2019","2019/04/01","","","10.1002/ejp.1396"
"30860681","Tapentadol in an Experimental Animal Model of Acute Orofacial Pain","Fricova J, Rokyta R, Nedvidek J.","Neuro Endocrinol Lett. 2019 Feb;39(7):496-500.","Fricova J","Neuro Endocrinol Lett","2019","2019/03/13","","",""
"30855723","Tapentadol immediate release for moderate to severe acute post-surgery pain","Viscusi ER, Allard R, Sohns M, Eerdekens M.","J Opioid Manag. 2019 Jan/Feb;15(1):51-67. doi: 10.5055/jom.2019.0486.","Viscusi ER","J Opioid Manag","2019","2019/03/12","","","10.5055/jom.2019.0486"
"30822619","Effects of the human SULT1A1 polymorphisms on the sulfation of acetaminophen,O-desmethylnaproxen, and tapentadol","Rasool MI, Bairam AF, Gohal SA, El Daibani AA, Alherz FA, Abunnaja MS, Alatwi ES, Kurogi K, Liu MC.","Pharmacol Rep. 2019 Apr;71(2):257-265. doi: 10.1016/j.pharep.2018.12.001. Epub 2018 Dec 10.","Rasool MI","Pharmacol Rep","2019","2019/03/02","PMC6498441","NIHMS1522689","10.1016/j.pharep.2018.12.001"
"30667206","Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action","Caputi FF, Nicora M, Simeone R, Candeletti S, Romualdi P.","Minerva Med. 2019 Feb;110(1):62-78. doi: 10.23736/S0026-4806.18.05909-8.","Caputi FF","Minerva Med","2019","2019/01/23","","","10.23736/S0026-4806.18.05909-8"
"30471002","Tapentadol Prolonged Release: A Review in Pain Management","Deeks ED.","Drugs. 2018 Nov;78(17):1805-1816. doi: 10.1007/s40265-018-1007-2.","Deeks ED","Drugs","2018","2018/11/25","PMC6422986","","10.1007/s40265-018-1007-2"
"30444145","A randomized controlled trial comparing tapentadol with oxycodone in non-breastfeeding women post elective cesarean section","Ffrench-O'Carroll R, Steinhaeuser H, Duff S, Close J, McNamara J, Ahmed N, Murray M, Rice T, Immanni S.","Curr Med Res Opin. 2019 Jun;35(6):975-981. doi: 10.1080/03007995.2018.1550059. Epub 2018 Dec 20.","Ffrench-O'Carroll R","Curr Med Res Opin","2019","2018/11/17","","","10.1080/03007995.2018.1550059"
"30380966","Comment on Gressler et al.: Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research","Radic T, Stollenwerk A, Elling C.","J Pain Palliat Care Pharmacother. 2018 Jun-Sep;32(2-3):192-193. doi: 10.1080/15360288.2018.1489444. Epub 2018 Oct 31.","Radic T","J Pain Palliat Care Pharmacother","2018","2018/11/02","","","10.1080/15360288.2018.1489444"
"30362140","Participation of ATP-sensitive K+ channels and μ-opioid receptors in the antinociceptive synergism of the paracetamol-tapentadol co-administration in the formalin-induced pain assay in mice","Zapata-Morales JR, Alonso-Castro ÁJ, Pérez-Gutiérrez S, Rojas-Bedolla EI, Sánchez-Enriquez S, Rivas-Carrillo JD, Serafín-Higuera NA, Isiordia-Espinoza MA.","Drug Dev Res. 2018 Dec;79(8):400-405. doi: 10.1002/ddr.21476. Epub 2018 Oct 26.","Zapata-Morales JR","Drug Dev Res","2018","2018/10/27","","","10.1002/ddr.21476"
"30350279","Quantitation of Tapentadol by Liquid Chromatography: Tandem Mass Spectrometry","Jones GR, Handy RP.","Methods Mol Biol. 2019;1872:61-65. doi: 10.1007/978-1-4939-8823-5_6.","Jones GR","Methods Mol Biol","2019","2018/10/24","","","10.1007/978-1-4939-8823-5_6"
"30274680","[Opioid switch and change of route of administration in cancer patients treated by morphine]","Michenot N, Rostaing S, Baron L, Faure S, Jovenin N, Hubault P, Delorme T, Collin E, Filbet M, Chvetzoff G, Delorme C, Minello C, Magnet M, Ammar D, Krakowski I, Poulain P.","Bull Cancer. 2018 Nov;105(11):1052-1073. doi: 10.1016/j.bulcan.2018.06.011. Epub 2018 Sep 29.","Michenot N","Bull Cancer","2018","2018/10/03","","","10.1016/j.bulcan.2018.06.011"
"30206823","Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'","Raffa RB, Elling C, Tzschentke TM.","Adv Ther. 2018 Oct;35(10):1471-1484. doi: 10.1007/s12325-018-0778-x. Epub 2018 Sep 11.","Raffa RB","Adv Ther","2018","2018/09/13","PMC6182641","","10.1007/s12325-018-0778-x"
"30200781","Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials","Lange B, Sohns M, Tempero J, Elling C.","Curr Med Res Opin. 2018 Dec;34(12):2113-2123. doi: 10.1080/03007995.2018.1520085. Epub 2018 Sep 17.","Lange B","Curr Med Res Opin","2018","2018/09/12","","","10.1080/03007995.2018.1520085"
"30079795","Toxicity of tapentadol: a systematic review","Channell JS, Schug S.","Pain Manag. 2018 Sep 1;8(5):327-339. doi: 10.2217/pmt-2018-0027. Epub 2018 Aug 6.","Channell JS","Pain Manag","2018","2018/08/07","","","10.2217/pmt-2018-0027"
"30042277","[Clinical Effects of Opioid Switching to Tapentadol - Retrospective Analysis of Efficacy and Adverse Effects]","Homma M, Kokubun H, Hayashi N, Kanai A, Atsuda K.","Gan To Kagaku Ryoho. 2018 Jul;45(7):1081-1086.","Homma M","Gan To Kagaku Ryoho","2018","2018/07/26","","",""
"29947490","Long-term, prolonged-release oral tapentadol for the treatment of refractory chronic low back pain: a single-center, observational study","Finco G, Mura P, Musu M, Deidda C, Saba M, Demelas I, Evangelista M, Sardo S.","Minerva Med. 2018 Aug;109(4):259-265. doi: 10.23736/S0026-4806.18.05641-0.","Finco G","Minerva Med","2018","2018/06/28","","","10.23736/S0026-4806.18.05641-0"
"29921501","Tapentadol - A representative of a new class of MOR-NRI analgesics","Zajączkowska R, Przewłocka B, Kocot-Kępska M, Mika J, Leppert W, Wordliczek J.","Pharmacol Rep. 2018 Aug;70(4):812-820. doi: 10.1016/j.pharep.2018.01.005. Epub 2018 Jan 31.","Zajączkowska R","Pharmacol Rep","2018","2018/06/21","","","10.1016/j.pharep.2018.01.005"
"29912416","The Increasing Use and Abuse of Tapentadol and Its Incorporation Into a Validated Quantitative Method","Partridge E, Teoh E, Nash C, Scott T, Charlwood C, Kostakis C.","J Anal Toxicol. 2018 Sep 1;42(7):485-490. doi: 10.1093/jat/bky027.","Partridge E","J Anal Toxicol","2018","2018/06/19","","","10.1093/jat/bky027"
"29861527","Is tapentadol a potential Trojan horse in the postdextropropoxyphene era in India?","Basu A, Mahadevan J, Ithal D, Selvaraj S, Chand PK, Murthy P.","Indian J Pharmacol. 2018 Jan-Feb;50(1):44-46. doi: 10.4103/ijp.IJP_21_17.","Basu A","Indian J Pharmacol","2018","2018/06/05","PMC5954633","","10.4103/ijp.IJP_21_17"
"29859025","[A simple method for quantification of tapentadol in dog plasma by liquid chromatography-tandem mass spectrometry and evaluation of the effects of conjugated metabolites on tapentadol]","Liang G, Lu YM, Dai XJ, Qin MJ, Zhong DF, Chen XY.","Yao Xue Xue Bao. 2016 Mar;51(3):434-8.","Liang G","Yao Xue Xue Bao","2016","2018/06/03","","",""
"29799633","Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study","Liu C, Li Y, Yang R, Zhang S, Zhao L, Zhang T.","Biomed Chromatogr. 2018 Oct;32(10):e4300. doi: 10.1002/bmc.4300. Epub 2018 Jul 16.","Liu C","Biomed Chromatogr","2018","2018/05/26","","","10.1002/bmc.4300"
"29777509","Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics","Li Y, Wang Y, Zhang R, Liu C, Wei Y, Sun J, He Z, Xu Y, Zhang T.","Drug Deliv Transl Res. 2018 Oct;8(5):1335-1344. doi: 10.1007/s13346-018-0524-6.","Li Y","Drug Deliv Transl Res","2018","2018/05/20","","","10.1007/s13346-018-0524-6"
"29675431","Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes","Tedeschi A, De Bellis A, Francia P, Bernini A, Perini M, Salutini E, Anichini R.","J Diabetes Res. 2018 Feb 20;2018:1081792. doi: 10.1155/2018/1081792. eCollection 2018.","Tedeschi A","J Diabetes Res","2018","2018/04/21","PMC5838502","","10.1155/2018/1081792"
"29650881","[Combination Therapy of Oxycodone and Tapentadol Was Effective for Intractable Pain Caused by Breast Cancer Bone Metastasis - A Case Report]","Matsuura T, Kusakabe A, Kessoku T, Honda Y, Yoshimi A, Goto A, Yoshida H, Sukegawa A, Nakajima A, Ichikawa Y.","Gan To Kagaku Ryoho. 2018 Mar;45(Suppl 1):74-76.","Matsuura T","Gan To Kagaku Ryoho","2018","2018/04/14","","",""
"29583048","Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs","Howard J, Aarnes TK, Dyce J, Lerche P, Wulf LW, Coetzee JF, Lakritz J.","Am J Vet Res. 2018 Apr;79(4):367-375. doi: 10.2460/ajvr.79.4.367.","Howard J","Am J Vet Res","2018","2018/03/28","","","10.2460/ajvr.79.4.367"
"29574444","Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol","Peacock A, Larance B, Farrell M, Cairns R, Buckley N, Degenhardt L.","BMJ Open. 2018 Mar 23;8(3):e020006. doi: 10.1136/bmjopen-2017-020006.","Peacock A","BMJ Open","2018","2018/03/26","PMC5875643","","10.1136/bmjopen-2017-020006"
"29551688","Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain","Torres-Sanchez S, Borges GDS, Mico JA, Berrocoso E.","Neuropharmacology. 2018 Jun;135:202-210. doi: 10.1016/j.neuropharm.2018.03.014. Epub 2018 Mar 15.","Torres-Sanchez S","Neuropharmacology","2018","2018/03/20","","","10.1016/j.neuropharm.2018.03.014"
"29506199","Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan","Sugiyama Y, Kataoka T, Tasaki Y, Kondo Y, Sato N, Naiki T, Sakamoto N, Akechi T, Kimura K.","Jpn J Clin Oncol. 2018 Apr 1;48(4):362-366. doi: 10.1093/jjco/hyy023.","Sugiyama Y","Jpn J Clin Oncol","2018","2018/03/06","","","10.1093/jjco/hyy023"
"29483406","[New Opioid Options in Japan - Methadone, Tapentadol and Hydromorphone]","Takagi Y, Aruga E.","Gan To Kagaku Ryoho. 2018 Feb;45(2):205-211.","Takagi Y","Gan To Kagaku Ryoho","2018","2018/02/28","","",""
"29441514","Treating postoperative pain in the patient who is in recovery or remission from opioid abuse: Focus on Tapentadol","Barkin RL, Barkin SJ.","J Opioid Manag. 2017 May/Jun;13(3):133-134. doi: 10.5055/jom.2017.0378.","Barkin RL","J Opioid Manag","2017","2018/02/15","","","10.5055/jom.2017.0378"
"29434240","Improved therapeutic potential of tapentadol employing cationic exchange resins as carriers in neuropathic pain: evidence from pharmacokinetic and pharmacodynamics study","Sharma M, Soni R.","Sci Rep. 2018 Feb 12;8(1):2812. doi: 10.1038/s41598-018-21214-2.","Sharma M","Sci Rep","2018","2018/02/14","PMC5809392","","10.1038/s41598-018-21214-2"
"29369473","Comparative pharmacology and toxicology of tramadol and tapentadol","Faria J, Barbosa J, Moreira R, Queirós O, Carvalho F, Dinis-Oliveira RJ.","Eur J Pain. 2018 May;22(5):827-844. doi: 10.1002/ejp.1196. Epub 2018 Feb 19.","Faria J","Eur J Pain","2018","2018/01/26","","","10.1002/ejp.1196"
"29336654","Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research","Gressler LE, Hammond DA, Painter JT.","J Pain Palliat Care Pharmacother. 2017 Sep-Dec;31(3-4):228-236. doi: 10.1080/15360288.2017.1416440. Epub 2018 Jan 16.","Gressler LE","J Pain Palliat Care Pharmacother","2017","2018/01/17","","","10.1080/15360288.2017.1416440"
"29314177","Assessment of the antinociceptive and ulcerogenic activity of the tapentadol-diclofenac combination in rodents","Zapata-Morales JR, Alonso-Castro ÁJ, Granados-Soto V, Sánchez-Enriquez S, Isiordia-Espinoza MA.","Drug Dev Res. 2018 Feb;79(1):38-44. doi: 10.1002/ddr.21420. Epub 2018 Jan 3.","Zapata-Morales JR","Drug Dev Res","2018","2018/01/10","","","10.1002/ddr.21420"
"29270779","Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic","Stollenwerk A, Sohns M, Heisig F, Elling C, von Zabern D.","Adv Ther. 2018 Jan;35(1):12-30. doi: 10.1007/s12325-017-0654-0. Epub 2017 Dec 21.","Stollenwerk A","Adv Ther","2018","2017/12/23","PMC5778188","","10.1007/s12325-017-0654-0"
"29258432","The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms","Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, Fierro D, Pace MC.","BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186/s12871-017-0461-9.","Passavanti MB","BMC Anesthesiol","2017","2017/12/21","PMC5735888","","10.1186/s12871-017-0461-9"
"29224919","Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System","Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, Green JL.","J Pain. 2018 Apr;19(4):439-453. doi: 10.1016/j.jpain.2017.11.007. Epub 2017 Dec 7.","Vosburg SK","J Pain","2018","2017/12/12","","","10.1016/j.jpain.2017.11.007"
"29137025","Tapentadol versus tramadol in the management of low back pain in the emergency department: Impact of use on the need for reassessments","Guillén-Astete CA, Cardona-Carballo C, de la Casa-Resino C.","Medicine (Baltimore). 2017 Nov;96(45):e8403. doi: 10.1097/MD.0000000000008403.","Guillén-Astete CA","Medicine (Baltimore)","2017","2017/11/16","PMC5690718","","10.1097/MD.0000000000008403"
"29115161","Pharmacokinetics of tapentadol in laying hens and its residues in eggs after multiple oral dose administration","De Vito V, Owen H, Marzoni M, Kim TW, Poapolathep A, Giorgi M.","Br Poult Sci. 2018 Feb;59(1):128-133. doi: 10.1080/00071668.2017.1401705. Epub 2017 Dec 19.","De Vito V","Br Poult Sci","2018","2017/11/09","","","10.1080/00071668.2017.1401705"
"29029015","An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers","van der Schrier R, Jonkman K, van Velzen M, Olofsen E, Drewes AM, Dahan A, Niesters M.","Br J Anaesth. 2017 Dec 1;119(6):1169-1177. doi: 10.1093/bja/aex295.","van der Schrier R","Br J Anaesth","2017","2017/10/14","","","10.1093/bja/aex295"
"28906155","The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review","Mercadante S.","Curr Med Res Opin. 2017 Nov;33(11):1965-1969. doi: 10.1080/03007995.2017.1379981. Epub 2017 Sep 21.","Mercadante S","Curr Med Res Opin","2017","2017/09/15","","","10.1080/03007995.2017.1379981"
"28862072","Intranasal delivery of tapentadol hydrochloride-loaded chitosan nanoparticles: formulation, characterisation and its in vivo evaluation","Javia A, Thakkar H.","J Microencapsul. 2017 Nov;34(7):644-658. doi: 10.1080/02652048.2017.1375038. Epub 2017 Sep 18.","Javia A","J Microencapsul","2017","2017/09/02","","","10.1080/02652048.2017.1375038"
"28729524","Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review","Khaja M, Lominadze G, Millerman K.","Am J Case Rep. 2017 Jul 21;18:817-821. doi: 10.12659/ajcr.904695.","Khaja M","Am J Case Rep","2017","2017/07/22","PMC5536129","","10.12659/ajcr.904695"
"28699105","Tapentadol in neuropathic pain cancer patients: a prospective open label study","Galiè E, Villani V, Terrenato I, Pace A.","Neurol Sci. 2017 Oct;38(10):1747-1752. doi: 10.1007/s10072-017-3035-1. Epub 2017 Jul 11.","Galiè E","Neurol Sci","2017","2017/07/13","","","10.1007/s10072-017-3035-1"
"28693439","Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone","Haeseler G, Schaefers D, Prison N, Ahrens J, Liu X, Karch A.","BMC Anesthesiol. 2017 Jul 11;17(1):91. doi: 10.1186/s12871-017-0383-6.","Haeseler G","BMC Anesthesiol","2017","2017/07/12","PMC5504600","","10.1186/s12871-017-0383-6"
"28689766","Acute administration of tramadol and tapentadol at effective analgesic and maximum tolerated doses causes hepato- and nephrotoxic effects in Wistar rats","Barbosa J, Faria J, Leal S, Afonso LP, Lobo J, Queirós O, Moreira R, Carvalho F, Dinis-Oliveira RJ.","Toxicology. 2017 Aug 15;389:118-129. doi: 10.1016/j.tox.2017.07.001. Epub 2017 Jul 6.","Barbosa J","Toxicology","2017","2017/07/11","","","10.1016/j.tox.2017.07.001"
"28683172","Opioids for cancer pain - an overview of Cochrane reviews","Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA.","Cochrane Database Syst Rev. 2017 Jul 6;7(7):CD012592. doi: 10.1002/14651858.CD012592.pub2.","Wiffen PJ","Cochrane Database Syst Rev","2017","2017/07/07","PMC6483487","","10.1002/14651858.CD012592.pub2"
"28537506","Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies","Lange B, von Zabern D, Elling C, Dubois C.","Curr Med Res Opin. 2017 Aug;33(8):1413-1422. doi: 10.1080/03007995.2017.1335188. Epub 2017 Jun 11.","Lange B","Curr Med Res Opin","2017","2017/05/25","","","10.1080/03007995.2017.1335188"
"28537501","Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study","Serrie A, Lange B, Steup A.","Curr Med Res Opin. 2017 Aug;33(8):1423-1432. doi: 10.1080/03007995.2017.1335189. Epub 2017 Jun 11.","Serrie A","Curr Med Res Opin","2017","2017/05/25","","","10.1080/03007995.2017.1335189"
"28526155","Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review","Vadivelu N, Chang D, Helander EM, Bordelon GJ, Kai A, Kaye AD, Hsu D, Bang D, Julka I.","Anesthesiol Clin. 2017 Jun;35(2):e1-e20. doi: 10.1016/j.anclin.2017.01.001. Epub 2017 Apr 14.","Vadivelu N","Anesthesiol Clin","2017","2017/05/21","","","10.1016/j.anclin.2017.01.001"
"28499616","Effective analgesic doses of tramadol or tapentadol induce brain, lung and heart toxicity in Wistar rats","Faria J, Barbosa J, Leal S, Afonso LP, Lobo J, Moreira R, Queirós O, Carvalho F, Dinis-Oliveira RJ.","Toxicology. 2017 Jun 15;385:38-47. doi: 10.1016/j.tox.2017.05.003. Epub 2017 May 9.","Faria J","Toxicology","2017","2017/05/14","","","10.1016/j.tox.2017.05.003"
"28434283","Considering tapentadol as a first-line analgesic: 14 questions","Pergolizzi JV Jr, Breve F, Taylor R Jr, Raffa RB, Strasburger SE, LeQuang JA.","Pain Manag. 2017 Jul;7(4):331-339. doi: 10.2217/pmt-2016-0063. Epub 2017 Apr 24.","Pergolizzi JV Jr","Pain Manag","2017","2017/04/25","","","10.2217/pmt-2016-0063"
"28429337","From acute to chronic pain: tapentadol in the progressive stages of this disease entity","Coluzzi F, Fornasari D, Pergolizzi J, Romualdi P.","Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1672-1683.","Coluzzi F","Eur Rev Med Pharmacol Sci","2017","2017/04/22","","",""
"28412373","Mechanistic evaluation of tapentadol in reducing the pain perception using in-vivo brain and spinal cord microdialysis in rats","Benade V, Nirogi R, Bhyrapuneni G, Daripelli S, Ayyanki G, Irappanavar S, Ponnamaneni R, Manoharan A.","Eur J Pharmacol. 2017 Aug 15;809:224-230. doi: 10.1016/j.ejphar.2017.04.013. Epub 2017 Apr 12.","Benade V","Eur J Pharmacol","2017","2017/04/17","","","10.1016/j.ejphar.2017.04.013"
"28242230","Thermal antinociception following oral administration of tapentadol in conscious cats","Doodnaught GM, Evangelista MC, Steagall PVM.","Vet Anaesth Analg. 2017 Mar;44(2):364-369. doi: 10.1016/j.vaa.2016.05.001. Epub 2017 Jan 7.","Doodnaught GM","Vet Anaesth Analg","2017","2017/03/01","","","10.1016/j.vaa.2016.05.001"
"28119437","Metabolic Patterns of Fentanyl, Meperidine, Methylphenidate, Tapentadol and Tramadol Observed in Urine, Serum or Plasma","Wu F, Slawson MH, Johnson-Davis KL.","J Anal Toxicol. 2017 May 1;41(4):289-299. doi: 10.1093/jat/bkx003.","Wu F","J Anal Toxicol","2017","2017/01/26","","","10.1093/jat/bkx003"
"28084045","Tapentadol for Cancer Pain Management: A Narrative Review","Carmona-Bayonas A, Jiménez Fonseca P, Virizuela Echaburu J.","Pain Pract. 2017 Nov;17(8):1075-1088. doi: 10.1111/papr.12556. Epub 2017 Feb 25.","Carmona-Bayonas A","Pain Pract","2017","2017/01/14","","","10.1111/papr.12556"
"28070880","On the Molecular Basis Underlying the Metabolism of Tapentadol Through Sulfation","Bairam AF, Rasool MI, Kurogi K, Liu MC.","Eur J Drug Metab Pharmacokinet. 2017 Oct;42(5):793-800. doi: 10.1007/s13318-016-0392-8.","Bairam AF","Eur J Drug Metab Pharmacokinet","2017","2017/01/11","","","10.1007/s13318-016-0392-8"
"27997452","Effect of Tapentadol on Splenic Cytokine Production in Mice","Franchi S, Amodeo G, Gandolla M, Moschetti G, Panerai AE, Sacerdote P.","Anesth Analg. 2017 Mar;124(3):986-995. doi: 10.1213/ANE.0000000000001669.","Franchi S","Anesth Analg","2017","2016/12/21","","","10.1213/ANE.0000000000001669"
"27987222","The Antinociceptive Effect of a Tapentadol-Ketorolac Combination in a Mouse Model of Trigeminal Pain is Mediated by Opioid Receptors and ATP-Sensitive K(+) Channels","Barreras-Espinoza I, Soto-Zambrano JA, Serafín-Higuera N, Zapata-Morales R, Alonso-Castro Á, Bologna-Molina R, Granados-Soto V, Isiordia-Espinoza MA.","Drug Dev Res. 2017 Feb;78(1):63-70. doi: 10.1002/ddr.21373. Epub 2016 Dec 16.","Barreras-Espinoza I","Drug Dev Res","2017","2016/12/18","","","10.1002/ddr.21373"
"27853999","Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach","Zhang L, Yan X, Nobe S, Zannikos P, Etropolski M, Nandy P.","Clin Drug Investig. 2017 Mar;37(3):273-283. doi: 10.1007/s40261-016-0482-z.","Zhang L","Clin Drug Investig","2017","2016/11/18","","","10.1007/s40261-016-0482-z"
"27844472","Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment","Hofmann JF, Lal A, Steffens M, Boettger R.","J Opioid Manag. 2016 Sep/Oct;12(5):323-331. doi: 10.5055/jom.2016.0349.","Hofmann JF","J Opioid Manag","2016","2016/11/16","","","10.5055/jom.2016.0349"
"27651507","Efficacy and Safety of Long-Term Administration of Tapentadol in Relieving Chronic Pancreatitis Pain","Iacobellis A, Seripa D, Palmieri O, Andriulli N, Latina P.","Pain Med. 2017 Apr 1;18(4):815-817. doi: 10.1093/pm/pnw220.","Iacobellis A","Pain Med","2017","2016/09/22","","","10.1093/pm/pnw220"
"27611642","Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data","Baron R, Eberhart L, Kern KU, Regner S, Rolke R, Simanski C, Tölle T.","Pain Pract. 2017 Jun;17(5):678-700. doi: 10.1111/papr.12515. Epub 2016 Oct 25.","Baron R","Pain Pract","2017","2016/09/10","","","10.1111/papr.12515"
"27580162","Comparative metabolism of tramadol and tapentadol: a toxicological perspective","Barbosa J, Faria J, Queirós O, Moreira R, Carvalho F, Dinis-Oliveira RJ.","Drug Metab Rev. 2016 Nov;48(4):577-592. doi: 10.1080/03602532.2016.1229788. Epub 2016 Sep 15.","Barbosa J","Drug Metab Rev","2016","2016/09/01","","","10.1080/03602532.2016.1229788"
"27568082","A tapentadol related fatality: Case report with postmortem concentrations","Cantrell FL, Mallett P, Aldridge L, Verilhac K, McIntyre IM.","Forensic Sci Int. 2016 Sep;266:e1-e3. doi: 10.1016/j.forsciint.2016.08.020. Epub 2016 Aug 18.","Cantrell FL","Forensic Sci Int","2016","2016/08/29","","","10.1016/j.forsciint.2016.08.020"
"27516366","Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis","Xiao JP, Li AL, Feng BM, Ye Y, Wang GJ.","Pain Med. 2017 Jan 1;18(1):14-24. doi: 10.1093/pm/pnw154.","Xiao JP","Pain Med","2017","2016/08/13","","","10.1093/pm/pnw154"
"27510567","Prediction of response to tapentadol in chronic low back pain","Reimer M, Hüllemann P, Hukauf M, Keller T, Binder A, Gierthmühlen J, Baron R.","Eur J Pain. 2017 Feb;21(2):322-333. doi: 10.1002/ejp.926. Epub 2016 Aug 11.","Reimer M","Eur J Pain","2017","2016/08/12","PMC5248647","","10.1002/ejp.926"
"27509314","Central antinociceptive effect of tapentadol is increased by nitric oxide synthase inhibitors","Bujalska-Zadrożny M, Wolińska R, Leśniak A, Sacharczuk M.","Behav Pharmacol. 2016 Oct;27(7):606-14. doi: 10.1097/FBP.0000000000000255.","Bujalska-Zadrożny M","Behav Pharmacol","2016","2016/08/11","","","10.1097/FBP.0000000000000255"
"27479625","Treating Painful Diabetic Peripheral Neuropathy: An Update","Snyder MJ, Gibbs LM, Lindsay TJ.","Am Fam Physician. 2016 Aug 1;94(3):227-34.","Snyder MJ","Am Fam Physician","2016","2016/08/02","","",""
"27448104","Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy","Rosario M, Francesco R, Sergio F, Niccolò GL, Alba F, Maurizio N, Sergio A, Stefania G, Filippo A.","Support Care Cancer. 2016 Oct;24(10):4451-5. doi: 10.1007/s00520-016-3351-7. Epub 2016 Jul 22.","Rosario M","Support Care Cancer","2016","2016/07/23","","","10.1007/s00520-016-3351-7"
"27435439","Effectiveness and tolerability of tapentadol sustained release in the Australian setting","Russo MA, Santarelli DM.","J Opioid Manag. 2016 May-Jun;12(3):187-96. doi: 10.5055/jom.2016.0331.","Russo MA","J Opioid Manag","2016","2016/07/21","","","10.5055/jom.2016.0331"
"27410530","Biomedicine: Move over, morphine","Crow JM.","Nature. 2016 Jul 14;535(7611):S4-6. doi: 10.1038/535S4a.","Crow JM","Nature","2016","2016/07/14","","","10.1038/535S4a"
"27317026","Comparative study of the neurotoxicological effects of tramadol and tapentadol in SH-SY5Y cells","Faria J, Barbosa J, Queirós O, Moreira R, Carvalho F, Dinis-Oliveira RJ.","Toxicology. 2016 Jun 1;359-360:1-10. doi: 10.1016/j.tox.2016.06.010. Epub 2016 Jun 15.","Faria J","Toxicology","2016","2016/06/19","","","10.1016/j.tox.2016.06.010"
"27295489","Evaluation of the antihyperalgesic effect of tapentadol in two human evoked pain models - the TapCapMentho pilot trial","Förster M, Helfert S, Dierschke R, Großkopf M, Hüllemann P, Keller T, Baron R, Binder A.","Expert Opin Pharmacother. 2016 Sep;17(13):1717-25. doi: 10.1080/14656566.2016.1201071. Epub 2016 Aug 10.","Förster M","Expert Opin Pharmacother","2016","2016/06/14","","","10.1080/14656566.2016.1201071"
"27224908","Methodological Issues in Conducting Pilot Trials in Chronic Pain as Randomized, Double-blind, Placebo-controlled Studies","Tominaga Y, Koga H, Uchida N, Wanibe M, Hirose K, Matsumura T, Okamoto A, Richarz U, Etropolski M.","Drug Res (Stuttg). 2016 Jul;66(7):363-70. doi: 10.1055/s-0042-107669. Epub 2016 May 25.","Tominaga Y","Drug Res (Stuttg)","2016","2016/05/26","","","10.1055/s-0042-107669"
"27169518","Isobolographic Analysis of the Interaction Between Tapentadol and Ketorolac in a Mouse Model of Visceral Pain","Zapata-Morales JR, Aragon-Martinez OH, Adriana Soto-Castro T, Alonso-Castro ÁJ, Castañeda-Santana DI, Isiordia-Espinoza MA.","Drug Dev Res. 2016 Jun;77(4):187-91. doi: 10.1002/ddr.21310. Epub 2016 May 12.","Zapata-Morales JR","Drug Dev Res","2016","2016/05/13","","","10.1002/ddr.21310"
"27084172","[Oxycodone/naloxone retard superior to tapentadol in the study]","Kathmann W.","MMW Fortschr Med. 2016 Mar 31;158(6):79. doi: 10.1007/s15006-016-8014-6.","Kathmann W","MMW Fortschr Med","2016","2016/04/17","","","10.1007/s15006-016-8014-6"
"27071595","[Preventing chronification]","Häckel A.","MMW Fortschr Med. 2016 Apr 14;158(7):71. doi: 10.1007/s15006-016-8070-y.","Häckel A","MMW Fortschr Med","2016","2016/04/14","","","10.1007/s15006-016-8070-y"
"27062079","Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain","Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Dogan C, Etropolski M, Eerdekens M.","Eur J Pain. 2016 Oct;20(9):1513-8. doi: 10.1002/ejp.875. Epub 2016 Apr 7.","Kress HG","Eur J Pain","2016","2016/04/11","PMC5071659","","10.1002/ejp.875"
"27048320","Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy","Brunetti GA, Palumbo G, Morano GS, Baldacci E, Carmosino I, Annechini G, Talone R, Kiflom S, Mastrogiacomo G, Grammatico S, Chisini M, Costa A, Tendas A, Scaramucci L, Giovannini M, Niscola P, Petrucci MT, Cartoni C.","Cardiovasc Hematol Agents Med Chem. 2016;14(1):68-74. doi: 10.2174/1871525714666160405110833.","Brunetti GA","Cardiovasc Hematol Agents Med Chem","2016","2016/04/07","","","10.2174/1871525714666160405110833"
"27017892","Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro-in vivo studies","Patil GB, Surana SJ.","Artif Cells Nanomed Biotechnol. 2017 May;45(3):505-514. doi: 10.3109/21691401.2016.1163713. Epub 2016 Mar 26.","Patil GB","Artif Cells Nanomed Biotechnol","2017","2016/03/29","","","10.3109/21691401.2016.1163713"
"26960895","[Dual effect prevents chronic course]","Kraus S.","MMW Fortschr Med. 2015 Dec 14;157(21-22):92. doi: 10.1007/s15006-015-7639-1.","Kraus S","MMW Fortschr Med","2015","2016/03/11","","","10.1007/s15006-015-7639-1"
"26856111","Tapentadol (Palexia®, Yantil®), administration orale","Duh D, Van Broeck D.","J Pharm Belg. 2015 Dec;(4):37-8.","Duh D","J Pharm Belg","2015","2016/02/10","","",""
"26814267","Diversion and Illicit Sale of Extended Release Tapentadol in the United States","Dart RC, Surratt HL, Le Lait MC, Stivers Y, Bebarta VS, Freifeld CC, Brownstein JS, Burke JJ, Kurtz SP, Dasgupta N.","Pain Med. 2016 Aug;17(8):1490-6. doi: 10.1093/pm/pnv032. Epub 2015 Dec 14.","Dart RC","Pain Med","2016","2016/01/28","PMC4975014","","10.1093/pm/pnv032"
"26809410","[Clinical Utility of Tapentadol]","Kanazawa K, Yoshizawa A, Ishigure H, Shimoda A, Hiratsuka R, Ikeda H, Yoshizawa T.","Gan To Kagaku Ryoho. 2015 Dec;42 Suppl 1:48-50.","Kanazawa K","Gan To Kagaku Ryoho","2015","2016/01/27","","",""
"26798023","Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain","Huntjens DR, Liefaard LC, Nandy P, Drenth HJ, Vermeulen A.","Clin Drug Investig. 2016 Mar;36(3):213-23. doi: 10.1007/s40261-015-0371-x.","Huntjens DR","Clin Drug Investig","2016","2016/01/23","","","10.1007/s40261-015-0371-x"
"26706288","The analgesic agent tapentadol inhibits calcitonin gene-related peptide release from isolated rat brainstem via a serotonergic mechanism","Greco MC, Navarra P, Tringali G.","Life Sci. 2016 Jan 15;145:161-5. doi: 10.1016/j.lfs.2015.12.032. Epub 2015 Dec 17.","Greco MC","Life Sci","2016","2015/12/27","","","10.1016/j.lfs.2015.12.032"
"26689063","[Sustained-release Opioids: Morphine, Oxycodone and Tapentadol]","Takahashi Y, Iseki M.","Masui. 2015 Nov;64(11):1133-40.","Takahashi Y","Masui","2015","2015/12/23","","",""
"26677859","Development and Evaluation of a Once-Daily Controlled Porosity Osmotic Pump of Tapentadol Hydrochloride","Thakkar HP, Pancholi N, Patel CV.","AAPS PharmSciTech. 2016 Oct;17(5):1248-60. doi: 10.1208/s12249-015-0463-1. Epub 2015 Dec 17.","Thakkar HP","AAPS PharmSciTech","2016","2015/12/19","","","10.1208/s12249-015-0463-1"
"26554630","Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial","Baron R, Jansen JP, Binder A, Pombo-Suarez M, Kennes L, Müller M, Falke D, Steigerwald I.","Pain Pract. 2016 Jun;16(5):600-19. doi: 10.1111/papr.12361. Epub 2015 Nov 11.","Baron R","Pain Pract","2016","2015/11/12","","","10.1111/papr.12361"
"26535967","Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain","Biondi DM, Xiang J, Etropolski M, Moskovitz B.","J Opioid Manag. 2015 Sep-Oct;11(5):393-403. doi: 10.5055/jom.2015.0289.","Biondi DM","J Opioid Manag","2015","2015/11/05","","","10.5055/jom.2015.0289"
"26492961","Chronic pain: the burden of disease and treatment innovations","Monti S, Caporali R.","Reumatismo. 2015 Oct 23;67(2):35-44. doi: 10.4081/reumatismo.2015.840.","Monti S","Reumatismo","2015","2015/10/24","","","10.4081/reumatismo.2015.840"
"26428249","Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial","Buynak R, Rappaport SA, Rod K, Arsenault P, Heisig F, Rauschkolb C, Etropolski M.","Clin Ther. 2015 Nov 1;37(11):2420-38. doi: 10.1016/j.clinthera.2015.08.014. Epub 2015 Oct 1.","Buynak R","Clin Ther","2015","2015/10/03","","","10.1016/j.clinthera.2015.08.014"
"26403220","Oral tapentadol for cancer pain","Wiffen PJ, Derry S, Naessens K, Bell RF.","Cochrane Database Syst Rev. 2015 Sep 25;2015(9):CD011460. doi: 10.1002/14651858.CD011460.pub2.","Wiffen PJ","Cochrane Database Syst Rev","2015","2015/09/26","PMC6483480","","10.1002/14651858.CD011460.pub2"
"26369569","Comparative Toxicity of Tapentadol and Tramadol Utilizing Data Reported to the National Poison Data System","Tsutaoka BT, Ho RY, Fung SM, Kearney TE.","Ann Pharmacother. 2015 Dec;49(12):1311-6. doi: 10.1177/1060028015604631. Epub 2015 Sep 14.","Tsutaoka BT","Ann Pharmacother","2015","2015/09/16","","","10.1177/1060028015604631"
"26293513","Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan","Chen YJ, Chiang CC, Huang PJ, Huang J, Karcher K, Li H.","Curr Med Res Opin. 2015 Nov;31(11):2001-9. doi: 10.1185/03007995.2015.1082992. Epub 2015 Sep 21.","Chen YJ","Curr Med Res Opin","2015","2015/08/22","","","10.1185/03007995.2015.1082992"
"26215077","Unique pharmacology of tapentadol for treating acute and chronic pain","Knezevic NN, Tverdohleb T, Knezevic I, Candido KD.","Expert Opin Drug Metab Toxicol. 2015;11(9):1475-92. doi: 10.1517/17425255.2015.1072169. Epub 2015 Jul 29.","Knezevic NN","Expert Opin Drug Metab Toxicol","2015","2015/07/29","","","10.1517/17425255.2015.1072169"
"26208762","Validation of the Hospital Anxiety and Depression Scale in Patients With Acute Low Back Pain","Turk DC, Dworkin RH, Trudeau JJ, Benson C, Biondi DM, Katz NP, Kim M.","J Pain. 2015 Oct;16(10):1012-21. doi: 10.1016/j.jpain.2015.07.001. Epub 2015 Jul 21.","Turk DC","J Pain","2015","2015/07/26","","","10.1016/j.jpain.2015.07.001"
"26206026","[Shingles symptoms are gone but not the pain]","Urban & Vogel.","MMW Fortschr Med. 2015 Jul 23;157(13):35. doi: 10.1007/s15006-015-3342-5.","Urban & Vogel","MMW Fortschr Med","2015","2015/07/25","","","10.1007/s15006-015-3342-5"
"26139740","Comparison of tapentadol with tramadol for analgesia after cardiac surgery","Iyer SK, Mohan G, Ramakrishnan S, Theodore S.","Ann Card Anaesth. 2015 Jul-Sep;18(3):352-60. doi: 10.4103/0971-9784.159805.","Iyer SK","Ann Card Anaesth","2015","2015/07/04","PMC4881703","","10.4103/0971-9784.159805"
"26095455","Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study","Baron R, Likar R, Martin-Mola E, Blanco FJ, Kennes L, Müller M, Falke D, Steigerwald I.","Pain Pract. 2016 Jun;16(5):580-99. doi: 10.1111/papr.12308. Epub 2015 Jun 12.","Baron R","Pain Pract","2016","2015/06/23","","","10.1111/papr.12308"
"26076171","A Randomized Controlled Trial on the Effect of Tapentadol and Morphine on Conditioned Pain Modulation in Healthy Volunteers","Martini C, van Velzen M, Drewes A, Aarts L, Dahan A, Niesters M.","PLoS One. 2015 Jun 15;10(6):e0128997. doi: 10.1371/journal.pone.0128997. eCollection 2015.","Martini C","PLoS One","2015","2015/06/16","PMC4467981","","10.1371/journal.pone.0128997"
"26061717","Opioid-induced constipation","Gyawali B, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y.","Scand J Gastroenterol. 2015;50(11):1331-8. doi: 10.3109/00365521.2015.1054423. Epub 2015 Jun 10.","Gyawali B","Scand J Gastroenterol","2015","2015/06/11","","","10.3109/00365521.2015.1054423"
"26048311","Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test","Lee H, De Vito V, Giorgi M, Yun H.","Eur J Pharmacol. 2015 Sep 5;762:350-6. doi: 10.1016/j.ejphar.2015.05.064. Epub 2015 Jun 3.","Lee H","Eur J Pharmacol","2015","2015/06/07","","","10.1016/j.ejphar.2015.05.064"
"26025117","Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?","Veal FC, Peterson GM.","Drugs Aging. 2015 Jun;32(6):419-26. doi: 10.1007/s40266-015-0268-7.","Veal FC","Drugs Aging","2015","2015/05/31","","","10.1007/s40266-015-0268-7"
"26017279","Tapentadol for chronic musculoskeletal pain in adults","Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J.","Cochrane Database Syst Rev. 2015 May 27;2015(5):CD009923. doi: 10.1002/14651858.CD009923.pub2.","Santos J","Cochrane Database Syst Rev","2015","2015/05/29","PMC7205027","","10.1002/14651858.CD009923.pub2"
"26013114","[Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy]","Lange T, Krings D, Waldmann-Rex S.","MMW Fortschr Med. 2015 Apr;157(157 Suppl 4):12-21. doi: 10.1007/s15006-015-2932-6. Epub 2015 Apr 8.","Lange T","MMW Fortschr Med","2015","2015/05/28","","","10.1007/s15006-015-2932-6"
"26010460","Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations","Bannister K, Patel R, Goncalves L, Townson L, Dickenson AH.","Pain. 2015 Sep;156(9):1803-11. doi: 10.1097/j.pain.0000000000000240.","Bannister K","Pain","2015","2015/05/27","","","10.1097/j.pain.0000000000000240"
"25985806","Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency","Eichenbaum G, Göhler K, Etropolski M, Steigerwald I, Pergolizzi J, Kim M, Vorsanger G.","J Opioid Manag. 2015 May-Jun;11(3):211-27. doi: 10.5055/jom.2015.0270.","Eichenbaum G","J Opioid Manag","2015","2015/05/20","","","10.5055/jom.2015.0270"
"25951899","Does therapeutic use of tapentadol cause false-positive urine screens for methadone or opiates?","Mullins ME, Hock K, Scott MG.","Clin Toxicol (Phila). 2015 Jun;53(5):493-4. doi: 10.3109/15563650.2015.1020114.","Mullins ME","Clin Toxicol (Phila)","2015","2015/05/09","","","10.3109/15563650.2015.1020114"
"25914912","Effectiveness of opioid analgesics in chronic noncancer pain","Ferrari R, Zanolin ME, Duse G, Visentin M.","Pain Pract. 2015 Mar;15(3):272-8. doi: 10.1111/papr.12176.","Ferrari R","Pain Pract","2015","2015/04/28","","","10.1111/papr.12176"
"25899167","Palexia crystals in gastrointestinal tract, a new entity associated with death following gastrointestinal hemorrhage","Calvaruso M, Sinagra E, Castellucci M, Spada M, Raimondo D, Rizzo AG.","Exp Toxicol Pathol. 2015 May-Jun;67(5-6):373-5. doi: 10.1016/j.etp.2015.03.003. Epub 2015 Apr 17.","Calvaruso M","Exp Toxicol Pathol","2015","2015/04/23","","","10.1016/j.etp.2015.03.003"
"25867124","Development and preliminary validation of an integrated efficacy-tolerability composite measure for the evaluation of analgesics","Katz NP, Mou J, Trudeau J, Xiang J, Vorsanger G, Orman C, Kim M.","Pain. 2015 Jul;156(7):1357-65. doi: 10.1097/j.pain.0000000000000186.","Katz NP","Pain","2015","2015/04/14","","","10.1097/j.pain.0000000000000186"
"25866038","Tapentadol--the evidence so far","Ramaswamy S, Chang S, Mehta V.","Anaesthesia. 2015 May;70(5):518-22. doi: 10.1111/anae.13080.","Ramaswamy S","Anaesthesia","2015","2015/04/14","","","10.1111/anae.13080"
"25640290","Validation of the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2) in acute low back pain","Dworkin RH, Turk DC, Trudeau JJ, Benson C, Biondi DM, Katz NP, Kim M.","J Pain. 2015 Apr;16(4):357-66. doi: 10.1016/j.jpain.2015.01.012. Epub 2015 Jan 29.","Dworkin RH","J Pain","2015","2015/02/03","","","10.1016/j.jpain.2015.01.012"
"25601980","Tapentadol toxicity in children","Borys D, Stanton M, Gummin D, Drott T.","Pediatrics. 2015 Feb;135(2):e392-6. doi: 10.1542/peds.2014-2096.","Borys D","Pediatrics","2015","2015/01/21","","","10.1542/peds.2014-2096"
"25600054","Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC-MS/MS","Hillewaert V, Pusecker K, Sips L, Verhaeghe T, de Vries R, Langhans M, Terlinden R, Timmerman P.","J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15;981-982:40-7. doi: 10.1016/j.jchromb.2014.12.013. Epub 2015 Jan 8.","Hillewaert V","J Chromatogr B Analyt Technol Biomed Life Sci","2015","2015/01/21","","","10.1016/j.jchromb.2014.12.013"
"25592091","Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review","Thakur D, Dickerson S, Kumar Bhutani M, Junor R.","Clin Ther. 2015 Jan 1;37(1):212-24. doi: 10.1016/j.clinthera.2014.12.001.","Thakur D","Clin Ther","2015","2015/01/17","","","10.1016/j.clinthera.2014.12.001"
"25576174","The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy","Gonçalves L, Friend LV, Dickenson AH.","Eur J Pharmacol. 2015 Feb 15;749:151-60. doi: 10.1016/j.ejphar.2014.11.032. Epub 2015 Jan 6.","Gonçalves L","Eur J Pharmacol","2015","2015/01/11","PMC4339205","","10.1016/j.ejphar.2014.11.032"
"25527976","Enantiomeric separation of tapentadol by capillary electrophoresis--study of chiral selectivity manipulation by various types of cyclodextrins","Znaleziona J, Fejős I, Ševčík J, Douša M, Béni S, Maier V.","J Pharm Biomed Anal. 2015 Feb;105:10-6. doi: 10.1016/j.jpba.2014.11.027. Epub 2014 Nov 22.","Znaleziona J","J Pharm Biomed Anal","2015","2014/12/22","","","10.1016/j.jpba.2014.11.027"
"25503691","[Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks]","Häuser W, Bernardy K, Maier C.","Schmerz. 2015 Feb;29(1):96-108. doi: 10.1007/s00482-014-1452-0.","Häuser W","Schmerz","2015","2014/12/16","","","10.1007/s00482-014-1452-0"
"25503082","A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy","Schwartz S, Etropolski MS, Shapiro DY, Rauschkolb C, Vinik AI, Lange B, Cooper K, Van Hove I, Haeussler J.","Clin Drug Investig. 2015 Feb;35(2):95-108. doi: 10.1007/s40261-014-0249-3.","Schwartz S","Clin Drug Investig","2015","2014/12/16","PMC4300409","","10.1007/s40261-014-0249-3"
"25485639","Tapentadol and nitric oxide synthase systems","Bujalska-Zadrożny M, Wolińska R, Gąsińska E, Nagraba Ł.","Behav Pharmacol. 2015 Apr;26(3):282-8. doi: 10.1097/FBP.0000000000000117.","Bujalska-Zadrożny M","Behav Pharmacol","2015","2014/12/09","","","10.1097/FBP.0000000000000117"
"25464550","[Neuropathic back pain origins verified or cannot be excluded. Comparative pain study: retard tapentadol versus an established fixed combination]","","MMW Fortschr Med. 2014 Oct 23;156(18):70-1.","","MMW Fortschr Med","2014","2014/12/04","","",""
"25424235","[Clinical and economical evaluation of new analgesics for the management of chronic pain]","Coluzzi F, Ruggeri M.","Recenti Prog Med. 2014 Nov;105(11):415-9. doi: 10.1701/1680.18402.","Coluzzi F","Recenti Prog Med","2014","2014/11/27","","","10.1701/1680.18402"
"25409951","[Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d]","Richter U, Waldmann-Rex S, Lehmann U.","Wien Klin Wochenschr. 2015 Jun;127(11-12):477-87. doi: 10.1007/s00508-014-0655-9. Epub 2014 Nov 20.","Richter U","Wien Klin Wochenschr","2015","2014/11/21","","","10.1007/s00508-014-0655-9"
"25384306","Case report of a fatal intoxication by Nucynta","Franco DM, Ali Z, Levine B, Middleberg RA, Fowler DR.","Am J Forensic Med Pathol. 2014 Dec;35(4):234-6. doi: 10.1097/PAF.0b013e3182887804.","Franco DM","Am J Forensic Med Pathol","2014","2014/11/11","","","10.1097/PAF.0b013e3182887804"
"25351028","[Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone]","Kern KU, Krings D, Waldmann-Rex S.","MMW Fortschr Med. 2014 Jul 24;156 Suppl 2:54-63.","Kern KU","MMW Fortschr Med","2014","2014/10/30","","",""
"25244069","Assessing abuse potential of new analgesic medications following market release: an evaluation of Internet discussion of tapentadol abuse","McNaughton EC, Black RA, Weber SE, Butler SF.","Pain Med. 2015 Jan;16(1):131-40. doi: 10.1111/pme.12547. Epub 2014 Sep 22.","McNaughton EC","Pain Med","2015","2014/09/23","","","10.1111/pme.12547"
"25243972","Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment","Butler SF, McNaughton EC, Black RA.","Pain Med. 2015 Jan;16(1):119-30. doi: 10.1111/pme.12524. Epub 2014 Sep 22.","Butler SF","Pain Med","2015","2014/09/23","","","10.1111/pme.12524"
"25141248","Combining opioid and adrenergic mechanisms for chronic pain","Smith HS, Raffa RB, Pergolizzi JV, Taylor R, Tallarida RJ.","Postgrad Med. 2014 Jul;126(4):98-114. doi: 10.3810/pgm.2014.07.2788.","Smith HS","Postgrad Med","2014","2014/08/21","","","10.3810/pgm.2014.07.2788"
"25133962","Acute postoperative pain relief with immediate-release tapentadol: randomized, double-blind, placebo-controlled study conducted in South Korea","Lee YK, Ko JS, Rhim HY, Lee EJ, Karcher K, Li H, Shapiro D, Lee HS.","Curr Med Res Opin. 2014 Dec;30(12):2561-70. doi: 10.1185/03007995.2014.954665. Epub 2014 Aug 27.","Lee YK","Curr Med Res Opin","2014","2014/08/19","","","10.1185/03007995.2014.954665"
"25108647","Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain","Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I.","Clin Ther. 2015 Jan 1;37(1):94-113. doi: 10.1016/j.clinthera.2014.07.005. Epub 2014 Aug 6.","Sánchez Del Águila MJ","Clin Ther","2015","2014/08/11","","","10.1016/j.clinthera.2014.07.005"
"25054392","Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain","Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M.","Pain Physician. 2014 Jul-Aug;17(4):329-43.","Kress HG","Pain Physician","2014","2014/07/24","","",""
"25019623","Spinal cord transection-induced allodynia in rats--behavioral, physiopathological and pharmacological characterization","M'Dahoma S, Bourgoin S, Kayser V, Barthélémy S, Chevarin C, Chali F, Orsal D, Hamon M.","PLoS One. 2014 Jul 14;9(7):e102027. doi: 10.1371/journal.pone.0102027. eCollection 2014.","M'Dahoma S","PLoS One","2014","2014/07/15","PMC4096923","","10.1371/journal.pone.0102027"
"24985410","Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials","Etropolski M, Kuperwasser B, Flügel M, Häufel T, Lange B, Rauschkolb C, Laschewski F.","Adv Ther. 2014 Jun;31(6):604-20. doi: 10.1007/s12325-014-0128-6. Epub 2014 Jul 2.","Etropolski M","Adv Ther","2014","2014/07/03","","","10.1007/s12325-014-0128-6"
"24983745","Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists","Strick V.","Curr Med Res Opin. 2014 Oct;30(10):2085-92. doi: 10.1185/03007995.2014.939166. Epub 2014 Jul 15.","Strick V","Curr Med Res Opin","2014","2014/07/02","","","10.1185/03007995.2014.939166"
"24965165","Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model","Ono H, Nakamura A, Kanbara T, Minami K, Shinohara S, Sakaguchi G, Kanemasa T.","J Pharmacol Sci. 2014;125(3):264-73. doi: 10.1254/jphs.14081fp. Epub 2014 Jun 25.","Ono H","J Pharmacol Sci","2014","2014/06/27","","","10.1254/jphs.14081fp"
"24944065","Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: results of in vitro laboratory analyses","Galia E, Williams Y, Van Hove B, Pergolizzi J, Etropolski M, Vorsanger G.","J Opioid Manag. 2014 May-Jun;10(3):149-58. doi: 10.5055/jom.2014.0203.","Galia E","J Opioid Manag","2014","2014/06/20","","","10.5055/jom.2014.0203"
"24930324","[Influence of tapentadol retard on functional parameters in patients with severe chronic pain--is there a benefit in daily life?]","Strohmeier M, Waldmann-Rex S, Schwenke K.","MMW Fortschr Med. 2013 Jul 25;155 Suppl 2:63-71. doi: 10.1007/s15006-013-1056-0.","Strohmeier M","MMW Fortschr Med","2013","2014/06/17","","","10.1007/s15006-013-1056-0"
"24926734","Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain","Mercadante S, Porzio G, Adile C, Aielli F, Cortegiani A, Dickenson A, Casuccio A.","Curr Med Res Opin. 2014 Oct;30(10):2063-8. doi: 10.1185/03007995.2014.934793. Epub 2014 Jun 27.","Mercadante S","Curr Med Res Opin","2014","2014/06/14","","","10.1185/03007995.2014.934793"
"24926510","Tapentadol. Acute or chronic pain: no therapeutic advance","","Prescrire Int. 2014 May;23(149):121-4.","","Prescrire Int","2014","2014/06/14","","",""
"24917026","Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach","Falk S, Patel R, Heegaard A, Mercadante S, Dickenson AH.","Eur J Pain. 2015 Feb;19(2):152-8. doi: 10.1002/ejp.530. Epub 2014 Jun 11.","Falk S","Eur J Pain","2015","2014/06/12","","","10.1002/ejp.530"
"24916058","Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis","Biondi DM, Xiang J, Etropolski M, Moskovitz B.","Clin Drug Investig. 2014 Aug;34(8):565-76. doi: 10.1007/s40261-014-0209-y.","Biondi DM","Clin Drug Investig","2014","2014/06/12","PMC4102827","","10.1007/s40261-014-0209-y"
"24906437","Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release","Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T.","Clin Drug Investig. 2014 Jul;34(7):501-11. doi: 10.1007/s40261-014-0204-3.","Imanaka K","Clin Drug Investig","2014","2014/06/08","PMC4062813","","10.1007/s40261-014-0204-3"
"24849638","Successful use of stellate ganglion block and a new centrally acting analgesic with dual mode of action in a resistant temporomandibular joint pain","Jones GP, Tripathi SS.","BMJ Case Rep. 2014 May 20;2014:bcr2013203308. doi: 10.1136/bcr-2013-203308.","Jones GP","BMJ Case Rep","2014","2014/05/23","PMC4039930","","10.1136/bcr-2013-203308"
"24848284","A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy","Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, Etropolski MS.","Diabetes Care. 2014 Aug;37(8):2302-9. doi: 10.2337/dc13-2291. Epub 2014 May 21.","Vinik AI","Diabetes Care","2014","2014/05/23","","","10.2337/dc13-2291"
"24823521","Cardiovascular abnormalities with single dose of tapentadol","Vachhani A, Barvaliya M, Naik V, Tripathi CB.","J Postgrad Med. 2014 Apr-Jun;60(2):189-91. doi: 10.4103/0022-3859.132341.","Vachhani A","J Postgrad Med","2014","2014/05/15","","","10.4103/0022-3859.132341"
"24750558","Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study","Baron R, Kern U, Müller M, Dubois C, Falke D, Steigerwald I.","Pain Pract. 2015 Jun;15(5):471-86. doi: 10.1111/papr.12199. Epub 2014 Apr 18.","Baron R","Pain Pract","2015","2014/04/23","","","10.1111/papr.12199"
"24738609","Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study","Baron R, Martin-Mola E, Müller M, Dubois C, Falke D, Steigerwald I.","Pain Pract. 2015 Jun;15(5):455-70. doi: 10.1111/papr.12200. Epub 2014 Apr 17.","Baron R","Pain Pract","2015","2014/04/18","","","10.1111/papr.12200"
"24713310","Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy","Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A.","Br J Anaesth. 2014 Jul;113(1):148-56. doi: 10.1093/bja/aeu056. Epub 2014 Apr 8.","Niesters M","Br J Anaesth","2014","2014/04/10","","","10.1093/bja/aeu056"
"24662320","Tapentadol inhibits calcitonin gene-related peptide release from rat brainstem in vitro","Greco MC, Lisi L, Currò D, Navarra P, Tringali G.","Peptides. 2014 Jun;56:8-13. doi: 10.1016/j.peptides.2014.03.009. Epub 2014 Mar 21.","Greco MC","Peptides","2014","2014/03/26","","","10.1016/j.peptides.2014.03.009"
"24611613","Use of the novel atypical opioid tapentadol in goats (Capra hircus): pharmacokinetics after intravenous, and intramuscular administration","Lavy E, Lee HK, Mabjeesh SJ, Sabastian C, Baker Y, Giorgi M.","J Vet Pharmacol Ther. 2014 Oct;37(5):518-21. doi: 10.1111/jvp.12123. Epub 2014 Mar 10.","Lavy E","J Vet Pharmacol Ther","2014","2014/03/12","","","10.1111/jvp.12123"
"24578192","The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol","Tzschentke TM, Christoph T, Kögel BY.","CNS Drugs. 2014 Apr;28(4):319-29. doi: 10.1007/s40263-014-0151-9.","Tzschentke TM","CNS Drugs","2014","2014/03/01","","","10.1007/s40263-014-0151-9"
"24576316","Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs","Kögel B, Terlinden R, Schneider J.","Vet Anaesth Analg. 2014 May;41(3):297-304. doi: 10.1111/vaa.12140. Epub 2014 Feb 27.","Kögel B","Vet Anaesth Analg","2014","2014/03/01","","","10.1111/vaa.12140"
"24574066","Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit","Cowan A, Raffa RB, Tallarida CS, Tallarida RJ, Christoph T, Schröder W, Tzschentke TM.","Eur J Pain. 2014 Sep;18(8):1148-56. doi: 10.1002/j.1532-2149.2014.00461.x. Epub 2014 Feb 26.","Cowan A","Eur J Pain","2014","2014/02/28","","","10.1002/j.1532-2149.2014.00461.x"
"24528146","Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain","Coluzzi F, Ruggeri M.","Curr Med Res Opin. 2014 Jun;30(6):1139-51. doi: 10.1185/03007995.2014.894501. Epub 2014 Mar 3.","Coluzzi F","Curr Med Res Opin","2014","2014/02/18","","","10.1185/03007995.2014.894501"
"24524594","Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy","Desai B, Freeman E, Huang E, Hung A, Knapp E, Breunig IM, McPherson ML, Shaya FT.","Expert Rev Clin Pharmacol. 2014 Mar;7(2):203-9. doi: 10.1586/17512433.2014.889562.","Desai B","Expert Rev Clin Pharmacol","2014","2014/02/15","","","10.1586/17512433.2014.889562"
"24516101","The noradrenergic component in tapentadol action counteracts μ-opioid receptor-mediated adverse effects on adult neurogenesis","Meneghini V, Cuccurazzu B, Bortolotto V, Ramazzotti V, Ubezio F, Tzschentke TM, Canonico PL, Grilli M.","Mol Pharmacol. 2014 May;85(5):658-70. doi: 10.1124/mol.113.091520. Epub 2014 Feb 10.","Meneghini V","Mol Pharmacol","2014","2014/02/12","","","10.1124/mol.113.091520"
"24488603","Opioid receptor gene expression in human neuroblastoma SH-SY5Y cells following tapentadol exposure","Caputi FF, Carretta D, Tzschentke TM, Candeletti S, Romualdi P.","J Mol Neurosci. 2014 Aug;53(4):669-76. doi: 10.1007/s12031-014-0235-5. Epub 2014 Feb 4.","Caputi FF","J Mol Neurosci","2014","2014/02/04","","","10.1007/s12031-014-0235-5"
"24437530","Opioids in the treatment of postoperative pain: old drugs with new options?","Raeder J.","Expert Opin Pharmacother. 2014 Mar;15(4):449-52. doi: 10.1517/14656566.2014.879292. Epub 2014 Jan 17.","Raeder J","Expert Opin Pharmacother","2014","2014/01/21","","","10.1517/14656566.2014.879292"
"24423420","Three newly approved analgesics: an update","Saraghi M, Hersh EV.","Anesth Prog. 2013 Winter;60(4):178-87. doi: 10.2344/0003-3006-60.4.178.","Saraghi M","Anesth Prog","2013","2014/01/16","PMC3891458","","10.2344/0003-3006-60.4.178"
"24372103","μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons","Sadeghi M, Tzschentke TM, Christie MJ.","Br J Pharmacol. 2015 Jan;172(2):460-8. doi: 10.1111/bph.12566. Epub 2014 Jul 1.","Sadeghi M","Br J Pharmacol","2015","2013/12/31","PMC4292960","","10.1111/bph.12566"
"24370606","Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse","Cepeda MS, Fife D, Kihm MA, Mastrogiovanni G, Yuan Y.","Clin J Pain. 2014 Dec;30(12):1051-6. doi: 10.1097/AJP.0000000000000067.","Cepeda MS","Clin J Pain","2014","2013/12/28","PMC4232297","","10.1097/AJP.0000000000000067"
"24353047","A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain","Etropolski M, Lange B, Goldberg J, Steup A, Rauschkolb C.","J Opioid Manag. 2013 Sep-Oct;9(5):343-56. doi: 10.5055/jom.2013.0177.","Etropolski M","J Opioid Manag","2013","2013/12/20","","","10.5055/jom.2013.0177"
"24353023","Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects","Zannikos PN, Smit JW, Stahlberg HJ, Wenge B, Hillewaert VM, Etropolski MS.","J Opioid Manag. 2013 Jul-Aug;9(4):291-300. doi: 10.5055/jom.2013.0171.","Zannikos PN","J Opioid Manag","2013","2013/12/20","","","10.5055/jom.2013.0171"
"24353022","Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study","Vorsanger GJ, Klopfer AM, Xiang J, Benson CJ, Moskovitz BL, Rosenthal NR.","J Opioid Manag. 2013 Jul-Aug;9(4):281-90. doi: 10.5055/jom.2013.0170.","Vorsanger GJ","J Opioid Manag","2013","2013/12/20","","","10.5055/jom.2013.0170"
"24279155","[Tapentadol - how does it work in chronic pain?]","","MMW Fortschr Med. 2013 Sep 26;155(16):44-5.","","MMW Fortschr Med","2013","2013/11/28","","",""
"24211722","Tapentadol enantiomers: Synthesis, physico-chemical characterization and cyclodextrin interactions","Fejős I, He Y, Völgyi G, Kazsoki A, Sun J, Chen W, Sohajda T, Szente L, Jiang X, Béni S.","J Pharm Biomed Anal. 2014 Jan;88:594-601. doi: 10.1016/j.jpba.2013.10.005. Epub 2013 Oct 14.","Fejős I","J Pharm Biomed Anal","2014","2013/11/12","","","10.1016/j.jpba.2013.10.005"
"24206632","Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats","Lee HK, Lebkowska-Wieruszewska B, Kim TW, Kowaski CJ, Giorgi M.","Vet J. 2013 Dec;198(3):620-4. doi: 10.1016/j.tvjl.2013.09.011. Epub 2013 Sep 17.","Lee HK","Vet J","2013","2013/11/12","","","10.1016/j.tvjl.2013.09.011"
"24129223","Tapentadol-ER for the treatment of diabetic peripheral neuropathy","Games G, Hutchison A.","Consult Pharm. 2013 Oct;28(10):672-5. doi: 10.4140/TCP.n.2013.672.","Games G","Consult Pharm","2013","2013/10/17","","","10.4140/TCP.n.2013.672"
"24121047","Commentary on: Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain","Dickenson AH.","Neurosci Lett. 2014 Mar 6;562:90. doi: 10.1016/j.neulet.2013.09.069. Epub 2013 Oct 10.","Dickenson AH","Neurosci Lett","2014","2013/10/15","","","10.1016/j.neulet.2013.09.069"
"24107159","[Polyneuropathic pain therapy with a patient suffering from generalized castrate- resistant prostate cancer -  clinical case report]","Holubec L, Mrázková P, Matějka VM, Fiala O, Fínek J.","Klin Onkol. 2013;26(5):354-7. doi: 10.14735/amko2013354.","Holubec L","Klin Onkol","2013","2013/10/11","","","10.14735/amko2013354"
"24051022","Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice","Christoph T, Schröder W, Tallarida RJ, De Vry J, Tzschentke TM.","J Pharmacol Exp Ther. 2013 Dec;347(3):794-801. doi: 10.1124/jpet.113.207704. Epub 2013 Sep 19.","Christoph T","J Pharmacol Exp Ther","2013","2013/09/21","","","10.1124/jpet.113.207704"
"24042351","Nonmedical use of tapentadol immediate release by college students","Dart RC, Bartelson BB, Adams EH.","Clin J Pain. 2014 Aug;30(8):685-92. doi: 10.1097/AJP.0000000000000001.","Dart RC","Clin J Pain","2014","2013/09/18","","","10.1097/AJP.0000000000000001"
"23969300","Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain","Meske DS, Xie JY, Oyarzo J, Badghisi H, Ossipov MH, Porreca F.","Neurosci Lett. 2014 Mar 6;562:91-6. doi: 10.1016/j.neulet.2013.08.017. Epub 2013 Aug 19.","Meske DS","Neurosci Lett","2014","2013/08/24","PMC4018237","NIHMS571347","10.1016/j.neulet.2013.08.017"
"23957433","Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists","Schwittay A, Schumann C, Litzenburger BC, Schwenke K.","J Pain Palliat Care Pharmacother. 2013 Aug;27(3):225-34. doi: 10.3109/15360288.2013.816406. Epub 2013 Aug 19.","Schwittay A","J Pain Palliat Care Pharmacother","2013","2013/08/21","","","10.3109/15360288.2013.816406"
"23937387","Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain","Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, Hirose K, Matsumura T.","Curr Med Res Opin. 2013 Oct;29(10):1399-409. doi: 10.1185/03007995.2013.831816. Epub 2013 Aug 23.","Imanaka K","Curr Med Res Opin","2013","2013/08/14","","","10.1185/03007995.2013.831816"
"23912473","Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain","Steigerwald I, Schenk M, Lahne U, Gebuhr P, Falke D, Hoggart B.","Clin Drug Investig. 2013 Sep;33(9):607-19. doi: 10.1007/s40261-013-0102-0.","Steigerwald I","Clin Drug Investig","2013","2013/08/06","PMC3751342","","10.1007/s40261-013-0102-0"
"23878616","Application of design of experiment for floating drug delivery of tapentadol hydrochloride","Jagdale SC, Patil S, Kuchekar BS.","Comput Math Methods Med. 2013;2013:625729. doi: 10.1155/2013/625729. Epub 2013 Jun 26.","Jagdale SC","Comput Math Methods Med","2013","2013/07/24","PMC3710648","","10.1155/2013/625729"
"23850177","Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study","Cepeda MS, Fife D, Ma Q, Ryan PB.","J Pain. 2013 Oct;14(10):1227-41. doi: 10.1016/j.jpain.2013.05.010. Epub 2013 Jul 10.","Cepeda MS","J Pain","2013","2013/07/16","","","10.1016/j.jpain.2013.05.010"
"23835764","Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain","Kwong WJ, Hammond G, Upmalis D, Okamoto A, Yang M, Kavanagh S.","Clin J Pain. 2013 Aug;29(8):664-72. doi: 10.1097/AJP.0b013e318274b695.","Kwong WJ","Clin J Pain","2013","2013/07/10","","","10.1097/AJP.0b013e318274b695"
"23709304","Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies","Merchant S, Provenzano D, Mody S, Ho KF, Etropolski M.","J Opioid Manag. 2013 Jan-Feb;9(1):51-61. doi: 10.5055/jom.2013.0147.","Merchant S","J Opioid Manag","2013","2013/05/28","","","10.5055/jom.2013.0147"
"23703422","Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain","Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C.","Pain Physician. 2013 May-Jun;16(3):E237-46.","Biondi D","Pain Physician","2013","2013/05/25","","",""
"23664814","Effect of tapentadol on neurons in the locus coeruleus","Torres-Sanchez S, Alba-Delgado C, Llorca-Torralba M, Mico JA, Berrocoso E.","Neuropharmacology. 2013 Sep;72:250-8. doi: 10.1016/j.neuropharm.2013.04.053. Epub 2013 May 7.","Torres-Sanchez S","Neuropharmacology","2013","2013/05/14","","","10.1016/j.neuropharm.2013.04.053"
"23647785","Tapentadol analgesic interaction with clonidine","Sanders P.","Pain Med. 2013 Jun;14(6):943-4. doi: 10.1111/pme.12134. Epub 2013 May 3.","Sanders P","Pain Med","2013","2013/05/08","","","10.1111/pme.12134"
"23587608","Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain","Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH.","Clin Ther. 2013 May;35(5):659-72. doi: 10.1016/j.clinthera.2013.03.016. Epub 2013 Apr 13.","Merchant S","Clin Ther","2013","2013/04/17","","","10.1016/j.clinthera.2013.03.016"
"23573727","[Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists]","Schwittay A.","MMW Fortschr Med. 2013 Jan 21;155(1):64. doi: 10.1007/s15006-013-0048-4.","Schwittay A","MMW Fortschr Med","2013","2013/04/12","","","10.1007/s15006-013-0048-4"
"23540512","Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids","Mercadante S, Porzio G, Aielli F, Adile C, Verna L, Ficorella C, Giarratano A, Casuccio A.","Curr Med Res Opin. 2013 Jun;29(6):661-6. doi: 10.1185/03007995.2013.791617. Epub 2013 Apr 17.","Mercadante S","Curr Med Res Opin","2013","2013/04/02","","","10.1185/03007995.2013.791617"
"23539277","[Prolonged-release tapentadol for phantom pain. A case series]","Kern KU, Bialas P, Fangmann D.","Schmerz. 2013 Apr;27(2):174-81. doi: 10.1007/s00482-013-1309-y.","Kern KU","Schmerz","2013","2013/03/30","","","10.1007/s00482-013-1309-y"
"23475406","Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study","Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I.","Adv Ther. 2013 Mar;30(3):229-59. doi: 10.1007/s12325-013-0015-6. Epub 2013 Mar 7.","Gálvez R","Adv Ther","2013","2013/03/12","","","10.1007/s12325-013-0015-6"
"23456796","Cancer pain management: what's new?","Gaertner J, Schiessl C.","Curr Pain Headache Rep. 2013 Apr;17(4):328. doi: 10.1007/s11916-013-0328-9.","Gaertner J","Curr Pain Headache Rep","2013","2013/03/05","","","10.1007/s11916-013-0328-9"
"23441974","Real-world treatment pattern and outcomes among patients who took tapentadol IR or oxycodone IR","Lin J, Chow W, Kim MS, Rupnow MF.","J Med Econ. 2013;16(5):685-90. doi: 10.3111/13696998.2013.780177. Epub 2013 Mar 14.","Lin J","J Med Econ","2013","2013/02/28","","","10.3111/13696998.2013.780177"
"23430163","Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users","Stoops WW, Glaser PE, Rush CR.","Psychopharmacology (Berl). 2013 Jul;228(2):255-62. doi: 10.1007/s00213-013-3031-y. Epub 2013 Feb 21.","Stoops WW","Psychopharmacology (Berl)","2013","2013/02/23","PMC3683084","NIHMS448506","10.1007/s00213-013-3031-y"
"23357834","Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations","Göhler K, Brett M, Smit JW, Rengelshausen J, Terlinden R.","Int J Clin Pharmacol Ther. 2013 Apr;51(4):338-48. doi: 10.5414/CP201722.","Göhler K","Int J Clin Pharmacol Ther","2013","2013/01/30","","","10.5414/CP201722"
"23340531","Efficacy of tapentadol ER for managing moderate to severe chronic pain","Afilalo M, Morlion B.","Pain Physician. 2013 Jan;16(1):27-40.","Afilalo M","Pain Physician","2013","2013/01/24","","",""
"23328938","Tapentadol extended release for chronic pain patients","Taylor R, Pergolizzi JV, Raffa RB.","Adv Ther. 2013 Jan;30(1):14-27. doi: 10.1007/s12325-013-0002-y. Epub 2013 Jan 15.","Taylor R","Adv Ther","2013","2013/01/19","","","10.1007/s12325-013-0002-y"
"23326931","[Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice]","Agbalaka A, Schwenke K, Litzenburger B.","MMW Fortschr Med. 2012 Dec 17;154 Suppl 4:123-30.","Agbalaka A","MMW Fortschr Med","2012","2013/01/19","","",""
"23316699","A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers","Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD.","Addiction. 2013 Jun;108(6):1095-106. doi: 10.1111/add.12114. Epub 2013 Mar 13.","Vosburg SK","Addiction","2013","2013/01/16","PMC3664924","NIHMS463183","10.1111/add.12114"
"23264317","Assessment of the abuse of tapentadol immediate release: the first 24 months","Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH.","J Opioid Manag. 2012 Nov-Dec;8(6):395-402. doi: 10.5055/jom.2012.0139.","Dart RC","J Opioid Manag","2012","2012/12/25","","","10.5055/jom.2012.0139"
"23253635","Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study","Cepeda MS, Fife D, Vo L, Mastrogiovanni G, Yuan Y.","J Pain. 2013 Feb;14(2):158-64. doi: 10.1016/j.jpain.2012.10.012. Epub 2012 Dec 17.","Cepeda MS","J Pain","2013","2012/12/21","","","10.1016/j.jpain.2012.10.012"
"23245241","Fundamental study of enantioselective HPLC separation of tapentadol enantiomers using cellulose-based chiral stationary phase in normal phase mode","Douša M, Lehnert P, Adamusová H, Bosáková Z.","J Pharm Biomed Anal. 2013 Feb 23;74:111-6. doi: 10.1016/j.jpba.2012.10.017. Epub 2012 Oct 24.","Douša M","J Pharm Biomed Anal","2013","2012/12/19","","","10.1016/j.jpba.2012.10.017"
"23229959","Effects of tapentadol on mechanical hypersensitivity in rats with ligatures of the infraorbital nerve versus the sciatic nerve","Michot B, Bourgoin S, Kayser V, Hamon M.","Eur J Pain. 2013 Jul;17(6):867-80. doi: 10.1002/j.1532-2149.2012.00259.x. Epub 2012 Dec 11.","Michot B","Eur J Pain","2013","2012/12/12","","","10.1002/j.1532-2149.2012.00259.x"
"23216013","Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States","Neil N, Merchant S, Provenzano D, Ogden K, Mody SH.","J Med Econ. 2013;16(2):307-17. doi: 10.3111/13696998.2012.756401. Epub 2012 Dec 14.","Neil N","J Med Econ","2013","2012/12/11","","","10.3111/13696998.2012.756401"
"23133884","[Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists]","Schwittay A, Schumann C, Litzenburger BC, Schwenke K.","MMW Fortschr Med. 2012 Oct 4;154 Suppl 3:85-93.","Schwittay A","MMW Fortschr Med","2012","2012/11/09","","",""
"23088194","Can tapentadol cause a false-positive urine drug screen result for amphetamine?","Tang S, Mullins ME, Braun BM, Hock KG, Scott MG, Guarino AH, Brasington RD.","Clin Toxicol (Phila). 2012 Dec;50(10):1174-5. doi: 10.3109/15563650.2012.735367. Epub 2012 Oct 22.","Tang S","Clin Toxicol (Phila)","2012","2012/10/24","PMC4392007","NIHMS458680","10.3109/15563650.2012.735367"
"23083009","Death due to apparent intravenous injection of tapentadol","Kemp W, Schlueter S, Smalley E.","J Forensic Sci. 2013 Jan;58(1):288-91. doi: 10.1111/j.1556-4029.2012.02299.x. Epub 2012 Oct 19.","Kemp W","J Forensic Sci","2013","2012/10/23","","","10.1111/j.1556-4029.2012.02299.x"
"23057488","Tapentadol in cancer pain management: a prospective open-label study","Mercadante S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C, Giarratano A, Casuccio A.","Curr Med Res Opin. 2012 Nov;28(11):1775-9. doi: 10.1185/03007995.2012.739151. Epub 2012 Oct 26.","Mercadante S","Curr Med Res Opin","2012","2012/10/13","","","10.1185/03007995.2012.739151"
"22966803","Letter: effects of oxycodone and tapentadol dosage on gastrointestinal function","Kim M, Vorsanger G.","Aliment Pharmacol Ther. 2012 Oct;36(7):688; author reply 689. doi: 10.1111/apt.12015.","Kim M","Aliment Pharmacol Ther","2012","2012/09/13","","","10.1111/apt.12015"
"22880304","[Dual mechanism of action of tapentadol]","","MMW Fortschr Med. 2012 Jun 28;154(12):70-1.","","MMW Fortschr Med","2012","2012/08/14","","",""
"22879537","Cross-reactivity of tapentadol specimens with DRI methadone enzyme immunoassay","Collins AA, Merritt AP, Bourland JA.","J Anal Toxicol. 2012 Oct;36(8):582-7. doi: 10.1093/jat/bks064. Epub 2012 Aug 9.","Collins AA","J Anal Toxicol","2012","2012/08/11","","","10.1093/jat/bks064"
"22850352","Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain","Lerner D, Chang H, Rogers WH, Benson C, Chow W, Kim MS, Biondi D.","J Occup Environ Med. 2012 Aug;54(8):933-8. doi: 10.1097/JOM.0b013e31825f31a1.","Lerner D","J Occup Environ Med","2012","2012/08/02","","","10.1097/JOM.0b013e31825f31a1"
"22845494","Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain","Kavanagh S, Kwong WJ, Hammond GC, Nelson W, Upmalis D, Yang M.","Pain Med. 2012 Sep;13(9):1110-20. doi: 10.1111/j.1526-4637.2012.01454.x. Epub 2012 Jul 30.","Kavanagh S","Pain Med","2012","2012/08/01","","","10.1111/j.1526-4637.2012.01454.x"
"22819437","Switching from methadone to tapentadol for cancer pain","Mercadante S, Ferrera P, Adile C.","J Pain Symptom Manage. 2012 Sep;44(3):e3-5. doi: 10.1016/j.jpainsymman.2012.03.005. Epub 2012 Jul 21.","Mercadante S","J Pain Symptom Manage","2012","2012/07/24","","","10.1016/j.jpainsymman.2012.03.005"
"22771148","Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs","Giorgi M, Meizler A, Mills PC.","Vet J. 2012 Dec;194(3):309-13. doi: 10.1016/j.tvjl.2012.05.019. Epub 2012 Jul 7.","Giorgi M","Vet J","2012","2012/07/10","","","10.1016/j.tvjl.2012.05.019"
"22698264","Mechanistic and functional differentiation of tapentadol and tramadol","Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kögel B, Schiene K, Straßburger W, Terlinden R, Tzschentke TM.","Expert Opin Pharmacother. 2012 Jul;13(10):1437-49. doi: 10.1517/14656566.2012.696097. Epub 2012 Jun 15.","Raffa RB","Expert Opin Pharmacother","2012","2012/06/16","","","10.1517/14656566.2012.696097"
"22621882","Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology","Giorgi M, Meizler A, Mills PC.","J Pharm Biomed Anal. 2012 Aug-Sep;67-68:148-53. doi: 10.1016/j.jpba.2012.04.020. Epub 2012 May 3.","Giorgi M","J Pharm Biomed Anal","2012","2012/05/25","","","10.1016/j.jpba.2012.04.020"
"22618801","Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR","Xu XS, Etropolski M, Upmalis D, Okamoto A, Lin R, Nandy P.","Pharm Res. 2012 Sep;29(9):2555-64. doi: 10.1007/s11095-012-0786-5. Epub 2012 May 23.","Xu XS","Pharm Res","2012","2012/05/24","","","10.1007/s11095-012-0786-5"
"22612188","Tapentadol (nucynta) for treatment of pain","Erlich DR, Bodine W.","Am Fam Physician. 2012 May 1;85(9):910-1.","Erlich DR","Am Fam Physician","2012","2012/05/23","","",""
"22543979","Postmortem distribution of tapentadol and N-desmethyltapentadol","Larson SJ, Pestaner J, Prashar SK, Bayard C, Zarwell LW, Pierre-Louis M.","J Anal Toxicol. 2012 Jul;36(6):440-3. doi: 10.1093/jat/bks041. Epub 2012 Apr 26.","Larson SJ","J Anal Toxicol","2012","2012/05/01","","","10.1093/jat/bks041"
"22461271","Clinical efficacy and safety of tapentadol immediate release in the postoperative setting","Daniels SE, Golf M.","J Am Podiatr Med Assoc. 2012 Mar-Apr;102(2):139-48. doi: 10.7547/1020139.","Daniels SE","J Am Podiatr Med Assoc","2012","2012/03/31","","","10.7547/1020139"
"22443293","Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study","Steigerwald I, Müller M, Davies A, Samper D, Sabatowski R, Baron R, Rozenberg S, Szczepanska-Szerej A, Gatti A, Kress HG.","Curr Med Res Opin. 2012 Jun;28(6):911-36. doi: 10.1185/03007995.2012.679254. Epub 2012 May 9.","Steigerwald I","Curr Med Res Opin","2012","2012/03/27","","","10.1185/03007995.2012.679254"
"22419754","Tapentadol (Palexia) for moderate to severe acute pain","","Drug Ther Bull. 2012 Mar;50(3):30-3. doi: 10.1136/dtb.2012.02.0092.","","Drug Ther Bull","2012","2012/03/16","","","10.1136/dtb.2012.02.0092"
"22417717","Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs","Obradovic M, Ikenberg R, Hertel N, Antoñanzas F, Gálvez R, Liedgens H.","Clin Ther. 2012 Apr;34(4):926-43. doi: 10.1016/j.clinthera.2012.02.011. Epub 2012 Mar 13.","Obradovic M","Clin Ther","2012","2012/03/16","","","10.1016/j.clinthera.2012.02.011"
"22411644","Role of tapentadol in pain management","Mendis V.","Br J Hosp Med (Lond). 2012 Mar;73(3):143-7. doi: 10.12968/hmed.2012.73.3.143.","Mendis V","Br J Hosp Med (Lond)","2012","2012/03/14","","","10.12968/hmed.2012.73.3.143"
"22405435","Recent advances in multimodal analgesia","Young A, Buvanendran A.","Anesthesiol Clin. 2012 Mar;30(1):91-100. doi: 10.1016/j.anclin.2011.12.002. Epub 2012 Jan 12.","Young A","Anesthesiol Clin","2012","2012/03/13","","","10.1016/j.anclin.2011.12.002"
"22366930","[Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies]","Merker M, Dinges G, Koch T, Kranke P, Morin AM.","Schmerz. 2012 Feb;26(1):16-26. doi: 10.1007/s00482-011-1132-2.","Merker M","Schmerz","2012","2012/02/28","","","10.1007/s00482-011-1132-2"
"22364286","Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine","Ikenberg R, Hertel N, Moore RA, Obradovic M, Baxter G, Conway P, Liedgens H.","J Med Econ. 2012;15(4):724-36. doi: 10.3111/13696998.2012.670174. Epub 2012 Mar 28.","Ikenberg R","J Med Econ","2012","2012/02/28","","","10.3111/13696998.2012.670174"
"22348605","A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans","Jeong ID, Camilleri M, Shin A, Iturrino J, Boldingh A, Busciglio I, Burton D, Ryks M, Rhoten D, Zinsmeister AR.","Aliment Pharmacol Ther. 2012 May;35(9):1088-96. doi: 10.1111/j.1365-2036.2012.05040.x. Epub 2012 Feb 21.","Jeong ID","Aliment Pharmacol Ther","2012","2012/02/22","","","10.1111/j.1365-2036.2012.05040.x"
"22316353","Tapentadol extended release: in adults with chronic pain","Hoy SM.","Drugs. 2012 Feb 12;72(3):375-93. doi: 10.2165/11208600-000000000-00000.","Hoy SM","Drugs","2012","2012/02/10","","","10.2165/11208600-000000000-00000"
"22310021","Pharmacology update: tapentadol for neuropathic pain","Pierce DM, Shipstone E.","Am J Hosp Palliat Care. 2012 Dec;29(8):663-6. doi: 10.1177/1049909111434634. Epub 2012 Feb 5.","Pierce DM","Am J Hosp Palliat Care","2012","2012/02/08","","","10.1177/1049909111434634"
"22308595","[Drug-induced analgesia. Etiology oriented pain therapy]","","MMW Fortschr Med. 2011 Dec 8;153(49-50):58-9.","","MMW Fortschr Med","2011","2012/02/08","","",""
"22197547","Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis","Tzschentke TM, Folgering JH, Flik G, De Vry J.","Neurosci Lett. 2012 Jan 24;507(2):151-5. doi: 10.1016/j.neulet.2011.12.008. Epub 2011 Dec 14.","Tzschentke TM","Neurosci Lett","2012","2011/12/27","","","10.1016/j.neulet.2011.12.008"
"22192161","Tapentadol for pain: a treatment evaluation","Hartrick CT, Rodríguez Hernandez JR.","Expert Opin Pharmacother. 2012 Feb;13(2):283-6. doi: 10.1517/14656566.2012.648616. Epub 2011 Dec 23.","Hartrick CT","Expert Opin Pharmacother","2012","2011/12/24","","","10.1517/14656566.2012.648616"
"22059194","Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients","Vorsanger G, Xiang J, Biondi D, Upmalis D, Delfgaauw J, Allard R, Moskovitz B.","Pain Res Manag. 2011 Jul-Aug;16(4):245-51. doi: 10.1155/2011/323985.","Vorsanger G","Pain Res Manag","2011","2011/11/08","PMC3202376","","10.1155/2011/323985"
"21939888","Tapentadol for multimodal pain management","Pasero C.","J Perianesth Nurs. 2011 Oct;26(5):343-6. doi: 10.1016/j.jopan.2011.06.001.","Pasero C","J Perianesth Nurs","2011","2011/09/24","","","10.1016/j.jopan.2011.06.001"
"21936091","[The goal is: fewer side effects, better compliance (interview by Wolfgang van den Bergh, Michael Hubert and Helmut Laschet)]","Martens K.","MMW Fortschr Med. 2011 Sep 8;153(36):10.","Martens K","MMW Fortschr Med","2011","2011/09/22","","",""
"21905968","Systematic review of tapentadol in chronic severe pain","Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, Kleijnen J, Stürzebecher S.","Curr Med Res Opin. 2011 Oct;27(10):1907-30. doi: 10.1185/03007995.2011.611494. Epub 2011 Sep 12.","Riemsma R","Curr Med Res Opin","2011","2011/09/13","","","10.1185/03007995.2011.611494"
"21819790","Determination of tapentadol and its metabolite N-desmethyltapentadol in urine and oral fluid using liquid chromatography with tandem mass spectral detection","Coulter C, Taruc M, Tuyay J, Moore C.","J Anal Toxicol. 2010 Oct;34(8):458-63. doi: 10.1093/jat/34.8.458.","Coulter C","J Anal Toxicol","2010","2011/08/09","","","10.1093/jat/34.8.458"
"21819789","Determination of tapentadol (Nucynta®) and N-desmethyltapentadol in authentic urine specimens by ultra-performance liquid chromatography-tandem mass spectrometry","Bourland JA, Collins AA, Chester SA, Ramachandran S, Backer RC.","J Anal Toxicol. 2010 Oct;34(8):450-7. doi: 10.1093/jat/34.8.450.","Bourland JA","J Anal Toxicol","2010","2011/08/09","","","10.1093/jat/34.8.450"
"21816956","Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain","Schiene K, De Vry J, Tzschentke TM.","J Pharmacol Exp Ther. 2011 Nov;339(2):537-44. doi: 10.1124/jpet.111.181263. Epub 2011 Aug 4.","Schiene K","J Pharmacol Exp Ther","2011","2011/08/06","","","10.1124/jpet.111.181263"
"21797962","Current considerations for the treatment of severe chronic pain: the potential for tapentadol","Pergolizzi J, Alegre C, Blake D, Alén JC, Caporali R, Casser HR, Correa-Illanes G, Fernandes P, Galilea E, Jany R, Jones A, Mejjad O, Morovic-Vergles J, Oteo-Álvaro Á, Radrigán Araya FJ, Simões ME, Uomo G.","Pain Pract. 2012 Apr;12(4):290-306. doi: 10.1111/j.1533-2500.2011.00487.x. Epub 2011 Jul 29.","Pergolizzi J","Pain Pract","2012","2011/07/30","","","10.1111/j.1533-2500.2011.00487.x"
"21748951","Tapentadol for pain; enoxaparin after prosthetic valve replacement","DeDea L.","JAAPA. 2011 Jul;24(7):14. doi: 10.1097/01720610-201107000-00002.","DeDea L","JAAPA","2011","2011/07/14","","","10.1097/01720610-201107000-00002"
"21725034","Recent advances in opioid prescription for chronic non-cancer pain","Snidvongs S, Mehta V.","Postgrad Med J. 2012 Feb;88(1036):66-72. doi: 10.1136/pgmj.2010.112045. Epub 2011 Jul 1.","Snidvongs S","Postgrad Med J","2012","2011/07/05","","","10.1136/pgmj.2010.112045"
"21689507","[Tapentadol is a new, strongly efficative analgeticum with dual effect mechanisms]","Staahl C, Drewes AM, Jensen NH.","Ugeskr Laeger. 2011 Jun 20;173(25):1796-9.","Staahl C","Ugeskr Laeger","2011","2011/06/22","","",""
"21646907","Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources","Cepeda MS, Sutton A, Weinstein R, Kim M.","Clin J Pain. 2012 Jan;28(1):8-13. doi: 10.1097/AJP.0b013e3182201983.","Cepeda MS","Clin J Pain","2012","2011/06/08","","","10.1097/AJP.0b013e3182201983"
"21640095","Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain","Christoph T, De Vry J, Schiene K, Tallarida RJ, Tzschentke TM.","Eur J Pharmacol. 2011 Sep;666(1-3):72-9. doi: 10.1016/j.ejphar.2011.05.029. Epub 2011 May 27.","Christoph T","Eur J Pharmacol","2011","2011/06/07","","","10.1016/j.ejphar.2011.05.029"
"21561031","Tapentadol: an initial analysis--follow-up","Nelson T, Brett V.","J Opioid Manag. 2011 Mar-Apr;7(2):87-8, 90-1; author reply 92.","Nelson T","J Opioid Manag","2011","2011/05/13","","",""
"21494892","Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride","Etropolski M, Kelly K, Okamoto A, Rauschkolb C.","Adv Ther. 2011 May;28(5):401-17. doi: 10.1007/s12325-011-0018-0. Epub 2011 Apr 13.","Etropolski M","Adv Ther","2011","2011/04/16","","","10.1007/s12325-011-0018-0"
"21476608","Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor","Hartrick CT, Rozek RJ.","CNS Drugs. 2011 May;25(5):359-70. doi: 10.2165/11589080-000000000-00000.","Hartrick CT","CNS Drugs","2011","2011/04/12","","","10.2165/11589080-000000000-00000"
"21350889","Perioperative considerations for ""new"" kids on the opioid block","Moyo J, Rashiq S.","Can J Anaesth. 2011 May;58(5):417-9, 419-22. doi: 10.1007/s12630-011-9476-8. Epub 2011 Feb 25.","Moyo J","Can J Anaesth","2011","2011/02/26","","","10.1007/s12630-011-9476-8"
"21343919","Opioid-induced constipation: challenges and therapeutic opportunities","Camilleri M.","Am J Gastroenterol. 2011 May;106(5):835-42; quiz 843. doi: 10.1038/ajg.2011.30. Epub 2011 Feb 22.","Camilleri M","Am J Gastroenterol","2011","2011/02/24","","","10.1038/ajg.2011.30"
"21285506","Four stereoisomers of the novel μ-opioid receptor agonist tapentadol hydrochloride","Ravikumar K, Sridhar B, Pradhan N, Khunt M.","Acta Crystallogr C. 2011 Feb;67(Pt 2):o71-6. doi: 10.1107/S0108270111001727. Epub 2011 Jan 20.","Ravikumar K","Acta Crystallogr C","2011","2011/02/03","","","10.1107/S0108270111001727"
"21262850","Synergistic interaction between the two mechanisms of action of tapentadol in analgesia","Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T, Tallarida RJ.","J Pharmacol Exp Ther. 2011 Apr;337(1):312-20. doi: 10.1124/jpet.110.175042. Epub 2011 Jan 24.","Schröder W","J Pharmacol Exp Ther","2011","2011/01/26","PMC3364495","","10.1124/jpet.110.175042"
"21258822","[Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]","Tzschentke TM, Christoph T, Schröder W, Englberger W, De Vry J, Jahnel U, Kögel BY.","Schmerz. 2011 Feb;25(1):19-25. doi: 10.1007/s00482-010-1004-1.","Tzschentke TM","Schmerz","2011","2011/01/25","","","10.1007/s00482-010-1004-1"
"21232580","The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice","Kögel B, De Vry J, Tzschentke TM, Christoph T.","Neurosci Lett. 2011 Mar 17;491(2):104-7. doi: 10.1016/j.neulet.2011.01.014. Epub 2011 Jan 11.","Kögel B","Neurosci Lett","2011","2011/01/15","","","10.1016/j.neulet.2011.01.014"
"21194601","Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain","Kwong WJ, Ozer-Stillman I, Miller JD, Haber NA, Russell MW, Kavanagh S.","Clin Ther. 2010 Sep;32(10):1768-81. doi: 10.1016/j.clinthera.2010.09.011.","Kwong WJ","Clin Ther","2010","2011/01/04","","","10.1016/j.clinthera.2010.09.011"
"21189520","[Tapentadol. Opioid analgesic and norepinephrine reuptake inhibitors]","Weichel C, Hecht B.","Med Monatsschr Pharm. 2010 Dec;33(12):454-60.","Weichel C","Med Monatsschr Pharm","2010","2010/12/31","","",""
"21187272","Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats","Bee LA, Bannister K, Rahman W, Dickenson AH.","Pain. 2011 Jan;152(1):131-9. doi: 10.1016/j.pain.2010.10.004. Epub 2010 Nov 5.","Bee LA","Pain","2011","2010/12/29","","","10.1016/j.pain.2010.10.004"
"21162697","Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C.","Curr Med Res Opin. 2011 Jan;27(1):151-62. doi: 10.1185/03007995.2010.537589.","Schwartz S","Curr Med Res Opin","2011","2010/12/18","","","10.1185/03007995.2010.537589"
"21090048","Pain medications: what you need to know","Jackson M, Dubose L.","Todays FDA. 2010 Sep-Oct;22(5):60-3.","Jackson M","Todays FDA","2010","2010/11/25","","",""
"21074743","Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol","Nossaman VE, Ramadhyani U, Kadowitz PJ, Nossaman BD.","Anesthesiol Clin. 2010 Dec;28(4):647-66. doi: 10.1016/j.anclin.2010.08.009.","Nossaman VE","Anesthesiol Clin","2010","2010/11/16","","","10.1016/j.anclin.2010.08.009"
"20960989","Analgesic update: tapentadol hydrochloride","Hersh EV, Golubic S, Moore PA.","Compend Contin Educ Dent. 2010 Oct;31(8):594-9; quiz 600, 603.","Hersh EV","Compend Contin Educ Dent","2010","2010/10/22","","",""
"20875374","A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects","Oh C, Rengelshausen J, Mangold B, Etropolski M, Rauschkolb C, Wang SS, Upmalis D, Häufel T.","Int J Clin Pharmacol Ther. 2010 Oct;48(10):678-87. doi: 10.5414/cpp48678.","Oh C","Int J Clin Pharmacol Ther","2010","2010/09/30","","","10.5414/cpp48678"
"20818833","Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain","Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P.","Clin Pharmacokinet. 2010 Oct;49(10):671-82. doi: 10.2165/11535390-000000000-00000.","Xu XS","Clin Pharmacokinet","2010","2010/09/08","","","10.2165/11535390-000000000-00000"
"20731478","Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain","Frampton JE.","Drugs. 2010 Sep 10;70(13):1719-43. doi: 10.2165/11204470-000000000-00000.","Frampton JE","Drugs","2010","2010/08/25","","","10.2165/11204470-000000000-00000"
"20659810","Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?","Kress HG.","Eur J Pain. 2010 Sep;14(8):781-3. doi: 10.1016/j.ejpain.2010.06.017. Epub 2010 Jul 24.","Kress HG","Eur J Pain","2010","2010/07/28","","","10.1016/j.ejpain.2010.06.017"
"20642251","Tapentadol: an initial analysis","Prommer EE.","J Opioid Manag. 2010 May-Jun;6(3):223-6. doi: 10.5055/jom.2010.0020.","Prommer EE","J Opioid Manag","2010","2010/07/21","","","10.5055/jom.2010.0020"
"20642246","Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain","Vorsanger G, Xiang J, Okamoto A, Upmalis D, Moskovitz B.","J Opioid Manag. 2010 May-Jun;6(3):169-79. doi: 10.5055/jom.2010.0015.","Vorsanger G","J Opioid Manag","2010","2010/07/21","","","10.5055/jom.2010.0015"
"20629605","Tapentadol for acute and chronic pain","Sloan P.","Expert Opin Pharmacother. 2010 Aug;11(11):1783-5. doi: 10.1517/14656566.2010.495870.","Sloan P","Expert Opin Pharmacother","2010","2010/07/16","","","10.1517/14656566.2010.495870"
"20602712","Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain","Wild JE, Grond S, Kuperwasser B, Gilbert J, McCann B, Lange B, Steup A, Häufel T, Etropolski MS, Rauschkolb C, Lange R.","Pain Pract. 2010 Sep-Oct;10(5):416-27. doi: 10.1111/j.1533-2500.2010.00397.x.","Wild JE","Pain Pract","2010","2010/07/07","","","10.1111/j.1533-2500.2010.00397.x"
"20586515","Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study","Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J.","Clin Drug Investig. 2010;30(8):489-505. doi: 10.2165/11533440-000000000-00000.","Afilalo M","Clin Drug Investig","2010","2010/07/01","","","10.2165/11533440-000000000-00000"
"20578811","Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study","Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, Lange B, Lange C, Etropolski M.","Expert Opin Pharmacother. 2010 Aug;11(11):1787-804. doi: 10.1517/14656566.2010.497720.","Buynak R","Expert Opin Pharmacother","2010","2010/06/29","","","10.1517/14656566.2010.497720"
"20556560","Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain","Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, Etropolski M.","Adv Ther. 2010 Jun;27(6):381-99. doi: 10.1007/s12325-010-0036-3. Epub 2010 Jun 11.","Lange B","Adv Ther","2010","2010/06/18","","","10.1007/s12325-010-0036-3"
"20541444","Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain","Schröder W, Vry JD, Tzschentke TM, Jahnel U, Christoph T.","Eur J Pain. 2010 Sep;14(8):814-21. doi: 10.1016/j.ejpain.2010.05.005. Epub 2010 Jun 11.","Schröder W","Eur J Pain","2010","2010/06/15","","","10.1016/j.ejpain.2010.05.005"
"20518601","Tapentadol immediate-release for acute pain","Hartrick CT.","Expert Rev Neurother. 2010 Jun;10(6):861-9. doi: 10.1586/ern.10.72.","Hartrick CT","Expert Rev Neurother","2010","2010/06/04","","","10.1586/ern.10.72"
"20465361","Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?","Candiotti KA, Gitlin MC.","Curr Med Res Opin. 2010 Jul;26(7):1677-84. doi: 10.1185/03007995.2010.483941.","Candiotti KA","Curr Med Res Opin","2010","2010/05/15","","","10.1185/03007995.2010.483941"
"20383344","In vitro and in vivo characterization of tapentadol metabolites","Terlinden R, Kogel BY, Englberger W, Tzschentke TM.","Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):31-8. doi: 10.1358/mf.2010.32.1.1434165.","Terlinden R","Methods Find Exp Clin Pharmacol","2010","2010/04/13","","","10.1358/mf.2010.32.1.1434165"
"20219399","Strong analgesics: working towards an optimal balance between efficacy and side effects","Varrassi G, Marinangeli F, Piroli A, Coaccioli S, Paladini A.","Eur J Pain. 2010 Apr;14(4):340-2. doi: 10.1016/j.ejpain.2010.02.006. Epub 2010 Mar 9.","Varrassi G","Eur J Pain","2010","2010/03/12","","","10.1016/j.ejpain.2010.02.006"
"20119464","Dose conversion between tapentadol immediate and extended release for low back pain","Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C.","Pain Physician. 2010 Jan-Feb;13(1):61-70.","Etropolski MS","Pain Physician","2010","2010/02/02","","",""
"20110020","Tapentadol hydrochloride: a centrally acting oral analgesic","Wade WE, Spruill WJ.","Clin Ther. 2009 Dec;31(12):2804-18. doi: 10.1016/j.clinthera.2009.12.003.","Wade WE","Clin Ther","2009","2010/01/30","","","10.1016/j.clinthera.2009.12.003"
"20092221","Is tapentadol an advance on tramadol?","Guay DR.","Consult Pharm. 2009 Nov;24(11):833-40. doi: 10.4140/tcp.n.2009.833.","Guay DR","Consult Pharm","2009","2010/01/23","","","10.4140/tcp.n.2009.833"
"20083979","New Drugs2010, PART 1","Hussar DA.","Nursing. 2010 Feb;40(2):36-45; quiz 45-7. doi: 10.1097/01.NURSE.0000367864.13317.2a.","Hussar DA","Nursing","2010","2010/01/20","","","10.1097/01.NURSE.0000367864.13317.2a"
"20030470","Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies","Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, Upmalis D, Mangold B.","Pharmacotherapy. 2010 Jan;30(1):25-34. doi: 10.1592/phco.30.1.25.","Smit JW","Pharmacotherapy","2010","2009/12/25","","","10.1592/phco.30.1.25"
"20026182","Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain","Christoph T, De Vry J, Tzschentke TM.","Neurosci Lett. 2010 Feb 12;470(2):91-4. doi: 10.1016/j.neulet.2009.12.020. Epub 2009 Dec 18.","Christoph T","Neurosci Lett","2010","2009/12/23","","","10.1016/j.neulet.2009.12.020"
"19834626","Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule","Tzschentke TM, Jahnel U, Kogel B, Christoph T, Englberger W, De Vry J, Schiene K, Okamoto A, Upmalis D, Weber H, Lange C, Stegmann JU, Kleinert R.","Drugs Today (Barc). 2009 Jul;45(7):483-96. doi: 10.1358/dot.2009.45.7.1395291.","Tzschentke TM","Drugs Today (Barc)","2009","2009/10/17","","","10.1358/dot.2009.45.7.1395291"
"19795998","Tapentadol immediate release for the relief of moderate-to-severe acute pain","Hartrick CT.","Expert Opin Pharmacother. 2009 Nov;10(16):2687-96. doi: 10.1517/14656560903313734.","Hartrick CT","Expert Opin Pharmacother","2009","2009/10/03","","","10.1517/14656560903313734"
"19748880","New drugs: tapentadol hydrochloride, tolvaptan, and benzyl alcohol","Hussar DA.","J Am Pharm Assoc (2003). 2009 Sep-Oct;49(5):704-8. doi: 10.1331/JAPhA.2009.09534.","Hussar DA","J Am Pharm Assoc (2003)","2009","2009/09/15","","","10.1331/JAPhA.2009.09534"
"19661853","Tapentadol (Nucynta)--a new analgesic","","Med Lett Drugs Ther. 2009 Aug 10;51(1318):61-2.","","Med Lett Drugs Ther","2009","2009/08/08","","",""
"19445652","A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain","Daniels S, Casson E, Stegmann JU, Oh C, Okamoto A, Rauschkolb C, Upmalis D.","Curr Med Res Opin. 2009 Jun;25(6):1551-61. doi: 10.1185/03007990902952825.","Daniels S","Curr Med Res Opin","2009","2009/05/19","","","10.1185/03007990902952825"
"19356073","Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes","Kneip C, Terlinden R, Beier H, Chen G.","Drug Metab Lett. 2008 Jan;2(1):67-75. doi: 10.2174/187231208783478434.","Kneip C","Drug Metab Lett","2008","2009/04/10","","","10.2174/187231208783478434"
"19302899","Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study","Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D.","Clin Ther. 2009 Feb;31(2):260-71. doi: 10.1016/j.clinthera.2009.02.009.","Hartrick C","Clin Ther","2009","2009/03/24","","","10.1016/j.clinthera.2009.02.009"
"19301989","Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study","Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C.","Curr Med Res Opin. 2009 May;25(5):1095-104. doi: 10.1185/03007990902816970.","Hale M","Curr Med Res Opin","2009","2009/03/24","","","10.1185/03007990902816970"
"19203298","A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain","Daniels SE, Upmalis D, Okamoto A, Lange C, Häeussler J.","Curr Med Res Opin. 2009 Mar;25(3):765-76. doi: 10.1185/03007990902728183.","Daniels SE","Curr Med Res Opin","2009","2009/02/11","","","10.1185/03007990902728183"
"19106337","Tapentadol approved as pain reliever","Thompson CA.","Am J Health Syst Pharm. 2009 Jan 1;66(1):8. doi: 10.2146/news090001.","Thompson CA","Am J Health Syst Pharm","2009","2008/12/25","","","10.2146/news090001"
"19020157","Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study","Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P.","Anesth Analg. 2008 Dec;107(6):2048-55. doi: 10.1213/ane.0b013e31818881ca.","Kleinert R","Anesth Analg","2008","2008/11/21","","","10.1213/ane.0b013e31818881ca"
"18851776","The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery","Stegmann JU, Weber H, Steup A, Okamoto A, Upmalis D, Daniels S.","Curr Med Res Opin. 2008 Nov;24(11):3185-96. doi: 10.1185/03007990802448056. Epub 2008 Oct 15.","Stegmann JU","Curr Med Res Opin","2008","2008/10/15","","","10.1185/03007990802448056"
"18819294","Tapentadol a 'realistic alternative' to strong opioids for severe pain","Pinn S.","Br J Hosp Med (Lond). 2008 Sep;69(9):499.","Pinn S","Br J Hosp Med (Lond)","2008","2008/09/30","","",""
"18062408","Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects","Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K.","Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep;32(3):163-9. doi: 10.1007/BF03190478.","Terlinden R","Eur J Drug Metab Pharmacokinet","2007","2007/12/08","","","10.1007/BF03190478"
"17656655","(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties","Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J.","J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. doi: 10.1124/jpet.107.126052. Epub 2007 Jul 26.","Tzschentke TM","J Pharmacol Exp Ther","2007","2007/07/28","","","10.1124/jpet.107.126052"
